Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT by Howard, Robert et al.
Journals Library
DOI 10.3310/eme07020
Minocycline 200 mg or 400 mg versus 
placebo for mild Alzheimer’s disease:  
the MADE Phase II, three-arm RCT 
Robert Howard, Olga Zubko, Richard Gray, Rosie Bradley, Emma Harper, Linda Kelly,  
Lynn Pank, John O’Brien, Chris Fox, Naji Tabet, Gill Livingston, Peter Bentham,  
Rupert McShane, Alistair Burns, Craig Ritchie, Suzanne Reeves, Simon Lovestone,  
Clive Ballard, Wendy Noble, Gordon Wilcock and Ramin Nilforooshan
Efficacy and Mechanism Evaluation
Volume 7 • Issue 2 • April 2020
ISSN 2050-4365

Minocycline 200 mg or 400 mg versus placebo
for mild Alzheimer’s disease: the MADE
Phase II, three-arm RCT
Robert Howardo ,1* Olga Zubkoo ,2 Richard Grayo ,3
Rosie Bradleyo ,4 Emma Harpero ,4 Linda Kellyo ,4
Lynn Panko ,4 John O’Brieno ,5 Chris Foxo ,6 Naji Tabeto ,7
Gill Livingstono ,1 Peter Benthamo ,8 Rupert McShaneo ,9
Alistair Burnso ,10 Craig Ritchieo ,11 Suzanne Reeveso ,1
Simon Lovestoneo ,9 Clive Ballardo ,12 Wendy Nobleo ,13
Gordon Wilcocko 14 and Ramin Nilforooshano15
1Division of Psychiatry, University College London, London, UK
2Department of Old Age Psychiatry, King’s College London, London, UK
3Nuffield Department of Population Health, University of Oxford, Oxford, UK
4Medical Research Council Population Health Research Unit, University of Oxford,
Oxford, UK
5Department of Psychiatry, University of Cambridge, Cambridge, UK
6Norwich Medical School, University of East Anglia, Norwich, UK
7Department of Old Age Psychiatry, University of Sussex, Brighton, UK
8The Barberry Centre, Birmingham and Solihull Mental Health NHS Foundation
Trust, Birmingham, UK
9Department of Psychiatry, University of Oxford, Oxford, UK
10Department of Old Age Psychiatry, University of Manchester, Manchester, UK
11Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
12Medical School, University of Exeter, Exeter, UK
13Department of Basic and Clinical Neuroscience, King’s College London, London, UK
14Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
15Abraham Cowley Unit, Surrey and Borders Partnership NHS Foundation Trust,
Redhill, UK
*Corresponding author
Declared competing interests of authors: Robert Howard reports membership of the Health
Technology Assessment (HTA) Commissioning Board between 2013 and 2018. John O’Brien reports
personal fees from TauRx Pharmaceuticals Ltd (Singapore) and GE Healthcare (Chicago, IL, USA),
Eli Lilly and Company (Indianapolis, IN, USA) and Eisai Co., Ltd (Tokyo, Japan), outside the submitted
work. Gill Livingston reports membership of the HTA Clinical Trials Board Associate from 2007 to
2010. Peter Bentham reports personal fees from TauRx Pharmaceuticals Ltd outside the submitted
work. Craig Ritchie reports other payments from Roche Holding AG (Basel, Switzerland), Nutricia
International B.V. (Zoetermeer, the Netherlands), Actinogen Medical (Sydney, NSW, Australia),
Kyowa Hakko Kirin Co., Ltd (Singapore), Biogen Inc. (Cambridge, MA, USA) and Merck Sharp & Dohme
Corp. (Kenilworth, NJ, USA) and grants from Janssen Pharmaceutica (Beerse, Belgium) outside the

submitted work. Simon Lovestone reports other from Janssen-Cilag Ltd (High Wycombe, UK) and
grants from AstraZeneca plc (Cambridge, UK) and European Federation of Pharmaceutical Industries
and Associations (Brussels, Belgium) outside the submitted work. In addition, Simon Lovestone has
patents issued and pending related to biomarkers for Alzheimer’s disease. He also reports membership
of the Efficacy and Mechanism Evaluation Strategy Group from 2015 to 2019 and of the Medical
Advisory Board of SomaLogic (Boulder, CO, USA) up to 2019 and other consultancy for Merck Sharp &
Dohme Corp., Eli Lilly and Company and Optum, Inc. (Eden Prairie, MN, USA). Clive Ballard reports
grants and personal fees from Acadia Pharmaceutical Company (San Diego, CA, USA) and Lundbeck A/S
(Copenhagen, Denmark) and personal fees from Roche Holding AG, Otusaka Pharmaceutical Co., Ltd
(Tokyo, Japan), Novartis International AG (Basel Switzerland), Eli Lilly and Company and Pfizer Inc.
(New York, NY, USA) outside the submitted work.
Published April 2020
DOI: 10.3310/eme07020
This report should be referenced as follows:
Howard R, Zubko O, Gray R, Bradley R, Harper E, Kelly L, et al. Minocycline 200 mg or 400 mg
versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT. Efficacy Mech
Eval 2020;7(2).

Efficacy and Mechanism Evaluation
ISSN 2050-4365 (Print)
ISSN 2050-4373 (Online)
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE)
(www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be
purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Efficacy and Mechanism Evaluation journal
Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME
programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.
EME programme
The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the
potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or
long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases
and treatments.
The programme support translational research into a wide range of new or repurposed interventions. These may include diagnostic
or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health
initiatives delivered in the NHS.
The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and
which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of
concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the
mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse
effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.
The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR),
with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research
(NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern
Ireland.
This report
The research reported in this issue of the journal was funded by the EME programme as project number 11/47/01. The
contractual start date was in June 2013. The final report began editorial review in April 2019 and was accepted for publication
in November 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing
up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to
thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for
damages or losses arising from material published in this report.
This report presents independent research. The views and opinions expressed by authors in this publication are those of the
authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department
of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR,
NETSCC, the EME programme or the Department of Health and Social Care.
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Howard et al. under the terms of a
commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for
the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health
Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief of Efficacy and Mechanism Evaluation and NIHR Journals Library
Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK
NIHR Journals Library Editors
Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. 
 Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Senior Clinical 
Professor Andrée Le May
Professor Matthias Beck
Dr Tessa Crilly
Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson
Ms Tara Lamont
Dr Catriona McDaid
Professor William McGuire
Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK
Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK
Professor James Raftery
Dr Rob Riemsma
Professor Helen Roberts
Professor Jonathan Ross
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK
Professor Jim Thornton
Professor Martin Underwood
Please visit the website for a list of editors: 
Editorial contact:  
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Minocycline 200 mg or 400 mg versus placebo for mild
Alzheimer’s disease: the MADE Phase II, three-arm RCT
Robert Howardo ,1* Olga Zubkoo ,2 Richard Grayo ,3 Rosie Bradleyo ,4
Emma Harpero ,4 Linda Kellyo ,4 Lynn Panko ,4 John O’Brieno ,5
Chris Foxo ,6 Naji Tabeto ,7 Gill Livingstono ,1 Peter Benthamo ,8
Rupert McShaneo ,9 Alistair Burnso ,10 Craig Ritchieo ,11
Suzanne Reeveso ,1 Simon Lovestoneo ,9 Clive Ballardo ,12
Wendy Nobleo ,13 Gordon Wilcocko 14 and Ramin Nilforooshano 15
1Division of Psychiatry, University College London, London, UK
2Department of Old Age Psychiatry, King’s College London, London, UK
3Nuffield Department of Population Health, University of Oxford, Oxford, UK
4Medical Research Council Population Health Research Unit, University of Oxford, Oxford, UK
5Department of Psychiatry, University of Cambridge, Cambridge, UK
6Norwich Medical School, University of East Anglia, Norwich, UK
7Department of Old Age Psychiatry, University of Sussex, Brighton, UK
8The Barberry Centre, Birmingham and Solihull Mental Health NHS Foundation Trust,
Birmingham, UK
9Department of Psychiatry, University of Oxford, Oxford, UK
10Department of Old Age Psychiatry, University of Manchester, Manchester, UK
11Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
12Medical School, University of Exeter, Exeter, UK
13Department of Basic and Clinical Neuroscience, King’s College London, London, UK
14Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
15Abraham Cowley Unit, Surrey and Borders Partnership NHS Foundation Trust, Redhill, UK
*Corresponding author robert.howard@ucl.ac.uk
Background: Minocycline is an anti-inflammatory drug and protects against the toxic effects of β-amyloid
in vitro and in animal models of Alzheimer’s disease. To the best of our knowledge, no randomised
placebo-controlled clinical trials in patients with Alzheimer’s disease looking at the efficacy and tolerability
of minocycline have been carried out.
Objectives: The trial investigated whether or not minocycline was superior to placebo in slowing down
the rate of decline in cognitive and functional ability over 2 years. The safety and tolerability of
minocycline were also assessed.
Design: A Phase II, three-arm, randomised, double-blind, multicentre trial with a semifactorial design.
Participants continued on trial treatment for up to 24 months.
Setting: Patients were identified from memory services, both within the 32 participating NHS trusts
and within the network of memory services supported by the Dementias and Neurodegenerative
Diseases Research Network (also known as DeNDRoN).
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Participants: Patients with standardised Mini Mental State Examination scores of > 23 points and with
Alzheimer’s disease assessed by the National Institute on Aging–Alzheimer’s Association’s criteria were
identified from memory services.
Intervention: Patients with mild Alzheimer’s disease were randomly allocated 1 : 1 : 1 to receive one of
three treatments: arm 1 – 400 mg per day of minocycline; arm 2 – 200 mg per day of minocycline; or
arm 3 – placebo. Patients continued treatment for 24 months. Participants, investigators and outcome
assessors were blind to treatment allocation.
Main outcome measures: Primary outcome measures were decline in standardised Mini Mental State
Examination and Bristol Activities of Daily Living Scale scores of combined minocycline treatment arms
versus placebo, as analysed by intention-to-treat repeated measures regression.
Results: Between 23 May 2014 and 14 April 2016, 554 participants were randomised. Of the 544
eligible participants, the mean age was 74.3 years and the average standardised Mini Mental State
Examination score was 26.4 points. A total of 252 serious adverse events were reported, with the most
common categories being neuropsychiatric and cardiocirculatory. Significantly fewer participants
completed treatment with 400 mg of minocycline [29% (53/184)] than 200 mg [62% (112/181)] or
placebo [64% (114/179)] (p < 0.0001), mainly because of gastrointestinal symptoms (p = 0.0008),
dermatological side effects (p = 0.02) and dizziness (p = 0.01). Assessment rates were also lower in the
400-mg treatment arm: 68% (119 of 174 expected) for standardised Mini Mental State Examination
scores at 24 months, compared with 82% (144/176) for the 200-mg treatment arm and 84% (140/167)
for the placebo arm. Decline in standardised Mini Mental State Examination scores over the 24-month
study period in the combined minocycline arms was similar to that in the placebo arm (4.1- vs. 4.3-point
reduction; p = 0.9), as was the decline in the 400- and 200-mg treatment arms (3.3 vs. 4.7 points;
p = 0.08). Likewise, worsening of Bristol Activities of Daily Living Scale scores over 24 months was
similar in all trial arms (5.7, 6.6 and 6.2 points in the 400-mg treatment arm, 200-mg treatment arm
and placebo arm, respectively; a p-value of 0.57 for minocycline vs. placebo and a p-value of 0.77 for
400 vs. 200 mg of minocycline). Results were similar in different patient subgroups and in sensitivity
analyses adjusting for missing data.
Limitations: Potential limitations of the study include that biomarkers were not used to confirm the
diagnosis of Alzheimer’s disease, as these and apolipoprotein E (APOE) genotyping are not routinely
available within the NHS. Compliance was also worse than expected and differential follow-up rates
were observed, with fewer assessments obtained for the 400-mg treatment arm than for the 200-mg
treatment and placebo arms.
Conclusions: Minocycline does not delay the progress of cognitive or functional impairment in people
with mild Alzheimer’s disease over a 2-year period. Minocycline at a dose of 400 mg is poorly tolerated
in this population.
Future work: The Minocycline in mild Alzheimer’s DiseasE (MADE) study provides a framework for a
streamlined trial design that can be usefully applied to test other disease-modifying therapies.
Trial registration: Current Controlled Trials ISRCTN16105064 and EudraCT 2013-000397-30.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical
Research Council and National Institute for Health Research (NIHR) partnership, and will be published
in full in Efficacy and Mechanism Evaluation; Vol. 7, No. 2. See the NIHR Journals Library website for
further project information.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Contents
List of tables xi
List of figures xiii
List of abbreviations xv
Plain English summary xvii
Scientific summary xix
Chapter 1 Introduction 1
Chapter 2 Methods 3
Objectives 3
Trial design 3
Ethics approval and research governance 3
Outcomes 4
Standardised Mini Mental State Examination 4
Bristol Activities of Daily Living Scale 4
Participants 4
Inclusion criteria 4
Exclusion criteria 5
Recruitment procedure 5
Screening 5
Trial treatment 5
Treatment preparation 6
Packaging and labelling 6
Storage and dispensing 6
Unblinding 6
Concomitant medication 7
Side effects 7
Treatment compliance 7
Drug accountability 8
Assessments 8
Baseline 8
2-week assessment 8
3-, 9-, 15- and 21-month assessments 8
6-, 12- and 18-month assessments 8
24-month assessment 8
Safety and tolerability 8
Randomisation and blinding 9
Ethics considerations 10
Patient and public involvement 10
Statistical considerations 11
Literature search 11
DOI: 10.3310/eme07020 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
ix
Chapter 3 Results 13
Chapter 4 Discussion 21
Acknowledgements 23
References 29
Appendix 1 Protocol changes 33
Appendix 2 Literature search 35
Appendix 3 Outcome measure response sheets and sample participant responses 37
Appendix 4 Additional figures and tables 45
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
x
List of tables
TABLE 1 Study time–event chart 9
TABLE 2 Baseline characteristics, by treatment allocation, for the 544 eligible patients 15
TABLE 3 Reasons for stopping treatment by treatment allocation 15
TABLE 4 Serious adverse events by treatment allocation 18
TABLE 5 Research Ethics Committee- and Medicines and Healthcare products
Regulatory Agency-approved amendments 33
TABLE 6 Literature search 35
TABLE 7 The sMMSE outcome measure response sheet 37
TABLE 8 Follow-up rates for sMMSE and BADLS by treatment arm and time point 45
TABLE 9 Skin toxicity incidence and severity by treatment arm 46
TABLE 10 Causes of death 46
TABLE 11 Line-by-line listings of categorised SAEs 53
DOI: 10.3310/eme07020 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xi

List of figures
FIGURE 1 Flow chart of participants through the trial 14
FIGURE 2 Change in sMMSE scores: baseline to 24 months’ follow-up 16
FIGURE 3 Change in BADLS scores: baseline to 24 months’ follow-up 17
FIGURE 4 Bristol Activities of Daily Living Scale: outcome measure responses sheet 38
FIGURE 5 Sample participant responses: BADLS responses for 12 months’ follow-up 42
FIGURE 6 Sample participant responses: sMMSE responses for 12 months’ follow-up 44
FIGURE 7 Proportion of participants taking trial treatment over time: Kaplan–Meier plot 47
FIGURE 8 Flow chart showing the completeness over time of participant follow-up 48
FIGURE 9 Change in sMMSE and BADLS scores from baseline to month 24 using
imputation methods 1 (a and b) and 2 (c and d) 49
FIGURE 10 Subgroup analyses of change in sMMSE score over 24 months for
minocycline (any dose) vs. placebo by baseline characteristics: duration of symptoms,
baseline sMMSE score, age and gender 51
FIGURE 11 Probability of (a) overall survival, (b) institutionalisation and (c) time to
death or institutionalisation by treatment arm: Kaplan–Meier survival plots 51
FIGURE 12 Average decline of sMMSE score split by baseline sMMSE score
(i.e. a score of 24–26 or 27–30 points) 53
DOI: 10.3310/eme07020 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xiii

List of abbreviations
Aβ β-amyloid
AD Alzheimer's disease
ALS amyotrophic lateral sclerosis
BADLS Bristol Activities of Daily
Living Scale
DeNDRoN Dementias and
Neurodegenerative Diseases
Research Network
GP general practitioner
IMP investigational medicinal
product
MADE Minocycline in Alzheimer's
Disease Efficacy
MMSE Mini Mental State Examination
MR modified release
NDPH Nuffield Department of
Population Health
NIA–AA National Institute on
Aging–Alzheimer’s Association
NIHR National Institute for Health
Research
NRES National Research Ethics Service
NSAID non-steroidal anti-inflammatory
drug
PI principal investigator
QP qualified person
REC Research Ethics Committee
SAE serious adverse event
SD standard deviation
SLE systemic lupus erythematosus
sMMSE standardised Mini Mental State
Examination
TSC Trial Steering Committee
DOI: 10.3310/eme07020 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xv

Plain English summary
Alzheimer’s disease affects about 700,000 people in the UK and, although there are drugtreatments that can modestly improve some of the symptoms, we do not yet have any treatments
that slow down the progression of dementia.
Minocycline is an antibiotic that has been shown to protect brain cells in a number of experimental and
animal models of Alzheimer’s disease. Minocycline is cheap and well tolerated. If it could significantly
slow down the course of Alzheimer’s disease, it could quickly be made available to large numbers of
people with Alzheimer’s disease worldwide. Although minocycline is probably one of the best current
candidates for Alzheimer’s disease modification, the current evidence can only suggest a potential benefit.
A clinical trial was conducted to determine definitively whether or not minocycline is effective in
slowing the decline in Alzheimer’s disease. Long-term treatment effects of minocycline were
investigated, with two doses of minocycline, on decline in cognitive function, including memory,
attention and language, and ability to carry out essential functions of daily living, such as getting
dressed, grooming and eating.
Unfortunately, the study found that minocycline treatment did not have any measurable effect in
slowing down the progression of Alzheimer’s disease. Participants who took minocycline showed
exactly the same worsening of their cognitive functioning and activities of daily living as those who
were allocated to placebo treatment. The trial also established that minocycline at the high dose is
poorly tolerated in patients with Alzheimer’s disease, whereas the low dose of minocycline is well
tolerated, with participants being no more likely to withdraw from trial medication than those
taking placebo.
One limitation of the study is that biomarkers were not used to confirm Alzheimer’s disease diagnosis,
as tests for biomarkers are not routinely available within the NHS. Compliance with medication was
also worse than expected, with few patients in the high-dose arm completing 2 years’ treatment and
only moderate compliance in the low-dose and placebo treatment arms. It was difficult to obtain
outcome assessments that resulted in unequal numbers of completed assessments across treatment
arms, which could have biased the study’s results. Having said that, additional analyses investigating
potential bias have, reassuringly, shown the same pattern of results.
Although disappointing, these results are important because they will guide further research into the
search for a treatment. There is currently much interest in treating inflammatory changes in the brain
in Alzheimer’s disease and, as minocycline is a potent anti-inflammatory drug, the study’s results will
show researchers which pathways they should focus on.
DOI: 10.3310/eme07020 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xvii

Scientific summary
Background
Alzheimer’s disease is a major public health issue, with approximately 700,000 people in the UK
suffering from dementia, some 400,000 of whom have Alzheimer’s disease. The imperative to discover
and develop treatments that can stop or at least delay disease progression is clear. None of the drug
treatments licensed for Alzheimer’s disease has been shown to affect progression of the illness and,
despite a better understanding of the pathogenesis of Alzheimer’s disease, clinical trials of potentially
disease-modifying treatments so far undertaken have had disappointing results.
There is a substantial body of evidence to indicate that minocycline may be neuroprotective in
neurodegenerative diseases such as Alzheimer’s disease. Although the primary neuroprotective target
of minocycline in the central nervous system is not known, the principal effects of minocycline include
inhibition of microglial activation, attenuation of apoptosis and suppression of the production of
reactive oxygen species. Minocycline is arguably the most promising off-patent candidate for
Alzheimer’s disease modification that is not currently in trials. Furthermore, minocycline is cheap and
well tolerated.
Objectives
The Minocycline in Alzheimer’s Disease Efficacy (MADE) trial was a multicentre, randomised controlled
trial in very mild Alzheimer’s disease that primarily aimed to determine whether or not minocycline
is superior to placebo in affecting the disease course, over a 2-year period, as measured by rate of
decline in cognition (assessed via the standardised Mini Mental State Examination score) and function
(assessed via the Bristol Activities of Daily Living Scale score). The study also compared the safety and
tolerability of minocycline at doses of 200 and 400 mg per day.
Methods
The MADE study was a Phase II, three-arm, randomised, double-blind, multicentre trial with a semifactorial
design. Patients with very mild Alzheimer’s disease (as assessed by having a standardised Mini Mental
State Examination score of > 23 points and assessed by the National Institute on Aging–Alzheimer’s
Association’s criteria) were identified from memory services, both within the 32 participating NHS trusts
and within the network of memory services supported by the Dementias and Neurodegenerative Diseases
Research Network.
Inclusion criteria were:
l a diagnosis of National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s
Disease Related Disorders Association (NINCDS–ADRDA)-possible or -probable Alzheimer’s disease
l a standardised Mini Mental State Examination score of > 23 points
l consent to participate or agreement to participate if capacity to give informed consent was lost
l renal and hepatic function within normal limits
l taking Alzheimer’s disease medication (i.e. memantine or cholinesterase inhibitor) on a stable dose
for at least 8 weeks.
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Exclusion criteria were:
l a known allergy to tetracycline antibiotics
l a serious or unstable medical condition that would represent contraindication to taking
trial medication.
Following informed consent and completion of baseline assessment, participants were randomly
allocated 1 : 1 : 1 to one of three treatment arms: arm 1 – 400 mg per day of minocycline; arm 2 –
200 mg per day of minocycline; or arm 3 – placebo. Participants continued treatment for 24 months.
Participants, investigators and outcome assessors were blind to treatment allocation.
Primary outcome measures were the decline in the standardised Mini Mental State Examination and
the Bristol Activities of Daily Living Scale scores of combined minocycline trial arms versus placebo.
Outcomes were analysed by intention-to-treat repeated measures regression.
The secondary research objectives were to:
l establish safety and tolerability of minocycline at doses of 200 and 400 mg per day in patients with
mild Alzheimer’s disease
l establish whether or not 400 mg per day of minocycline offers superior neuroprotection than
200 mg per day of minocycline
l estimate the magnitude of effect sizes on cognitive and functional decline associated with any
statistically significant positive treatment effects that will inform the design and powering of a
future Phase III trial of definitive clinical effectiveness within the NHS.
Results
Between 23 May 2014 and 14 April 2016, 554 participants from 32 UK memory clinics were
randomised. For the 544 eligible participants, the mean age was 74.3 years and the average
standardised Mini Mental State Examination score was 26.4 points. Significantly fewer participants
completed 400 mg of minocycline treatment (29%, 53/184) than 200 mg of minocycline treatment
(62%, 112/181) or placebo (64%, 114/179) (p < 0.0001), mainly because of gastrointestinal symptoms
(p = 0.0008), dermatological side effects (p = 0.02) and dizziness (p = 0.01). Assessment rates were also
lower in the 400 mg of minocycline treatment arm for standardised Mini Mental State Examination
scores at 24 months [68% (119/174 expected) for 400 mg of minocycline vs. 82% (144/176) for
200 mg of minocycline vs. 84% (140/167) for placebo]. Decline in the standardised Mini Mental State
Examination scores over the 24-month study period in the combined minocycline trial arms were
similar to those in the placebo arm (4.1- vs. 4.3-point reduction; p = 0.9), as was the decline in the 400
and 200 mg of minocycline treatment arms (3.3 vs. 4.7 points; p = 0.08). Likewise, worsening of Bristol
Activities of Daily Living Scale scores over 24 months was similar in all treatment arms (5.7 for the
400 mg of minocycline treatment arm, 6.6 for the 200 mg of minocycline treatment arm and 6.2 for the
placebo arm; a p-value of 0.57 for minocycline vs. placebo, and a p-value of 0.77 for 400 vs. 200 mg of
minocycline). Results were similar in different patient subgroups and in sensitivity analyses adjusting for
missing data.
Conclusions
The MADE trial has shown that, in patients with mild Alzheimer’s disease, 24 months of minocycline
treatment at the doses tested does not delay the progress of cognitive or functional impairment,
as measured by the well-validated and widely used standardised Mini Mental State Examination
and Bristol Activities of Daily Living Scale clinical rating scales. The trial has also established that
SCIENTIFIC SUMMARY
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minocycline at a dose of 400 mg is poorly tolerated in this population, with fewer than one-third of
participants completing 24 months’ treatment. By contrast, 200 mg per day of minocycline is well
tolerated, with participants allocated this treatment being no more likely to withdraw from trial
medication than those taking placebo.
Future work
The MADE study provides a framework for a streamlined trial design that can be usefully applied to
test other disease-modifying therapies.
Trial registration
This trial is registered as ISRCTN16105064 and EudraCT 2013-000397-30.
Funding
This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research
Council and National Institute for Health Research (NIHR) partnership, and will be published in full
in Efficacy and Mechanism Evaluation; Vol. 7, No. 2. See the NIHR Journals Library website for further
project information.
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Chapter 1 Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that currently affects 50million people worldwide,1 with projected numbers of affected people reaching 135.5 million by
2050 and associated costs, just for the USA, at US$1.2T.2 At the Dementia Summit in 2013, the G8
health ministers committed to identifying a cure or a disease-modifying therapy for dementia by 2025,2
but no treatments have so far been shown to delay the progression of cognitive and functional
disability that characterises AD. Failure of treatment approaches directed at preventing the associated
build-up of β-amyloid (Aβ) or tau protein deposits has stimulated investigation of alternative treatment
approaches, including targeting inflammation in the brain.
The risk of developing AD is associated with immune-related and inflammatory genes, including genes
coding for myeloid-specific sialic acid-binding receptor (CD33), triggering receptor expressed on
myeloid cell 2 (TREM2), complement receptor 1 (CR1) and bridging integrator 1 (BIN1).3 Microglial
activation is increased in AD.4 Aβ is a pro-inflammatory agent in AD5 and several microglial surface
receptors are also Aβ receptors.6 In the early stages of AD, microglia clear Aβ by phagocytosis and
produce Aβ-degrading enzymes.7 However, as AD pathology progresses, accumulation of Aβ stimulates
the microglial production of pro-inflammatory agents, which drives further neurodegeneration.7
Two independent systematic reviews of mechanisms, tolerability, brain penetration, epidemiology and
early phase trial efficacy data on several classes of repositioned drugs have identified minocycline
among the most promising of these agents to progress to clinical trials in patients with AD.8,9
Minocycline is an anti-inflammatory tetracycline that crosses the blood–brain barrier and inhibits
the pro-inflammatory functions of microglia, and there is a substantial body of evidence to indicate
that minocycline may be neuroprotective in neurodegenerative diseases. Although the primary
neuroprotective target of minocycline in the central nervous system is not known, the principal effects
of minocycline include inhibition of microglial activation, attenuation of apoptosis and suppression of
the production of reactive oxygen species.10 In vitro, minocycline protects against Aβ-induced cell death
and prevents fibrillisation of Aβ.11 In transgenic mice, minocycline prevents Aβ deposition and neuronal
death,12 reduces tau phosphorylation and insoluble tau aggregates,13 downregulates inducible nitric
oxide synthetase, cyclo-oxygenase-2 and Aβ precursor protein-cleaving enzyme 1 (BACE1)14 and
protects hippocampal neurogenesis in the presence of Aβ.15 Minocycline reduces interleukin and
tumour necrosis factor alpha (TNFα) levels in mice,16 and neuronal death and learning deficits in
rats, following Aβ administration.17 In stroke patients, open-label treatment with 200 mg per day of
minocycline for 5 days after infarct has been reported to improve functional outcome.18 In animal
models of Parkinson’s disease, studies have reported both reduced microglial activation and neuronal
death19,20 and reduced microglial activation and worsened neuronal death.21,22 Pilot clinical trials in
Parkinson’s disease at a dose of 200 mg per day of minocycline over 18 months have shown no effect
on symptoms and no significant increase in adverse events.23
Minocycline treatment in the superoxide dismutase 1 transgenic mouse model for amyotrophic lateral
sclerosis (ALS) delayed the onset of neurodegeneration and muscle strength decline.24 A completed
Phase III trial in ALS, however, reported worse outcomes with minocycline in terms of faster decline in
forced vital capacity and manual muscle strength.25
Suggested explanations for this faster decline is that the dose of up to 400 mg per day of minocycline
may have contributed to fatigue in a highly susceptible population, and that increased levels of
glutamate receptor 1 phosphorylation may have promoted glutamate toxicity to motor neurons.26 In
AD, both in vitro and in vivo studies have shown reduced microglial activation, attenuated neuronal
death, astrogliosis and improved behavioural performance.11–13,17,27–31 However, to date, there have been
no published clinical trials in AD patients and none is currently registered as recruiting.
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The minimum daily dose of minocycline that offers neuroprotection in humans has not been
established. A dose of 200 mg per day of minocycline is generally very well tolerated in the long-term
treatment of acne32 and has been shown to be neuroprotective in acute stroke,18 spinal cord injury33
and multiple sclerosis.34 However, 200 mg per day of minocycline, although well tolerated, did not
improve outcomes in trials in Parkinson’s disease23 or Huntington’s disease.35 Some authors have
argued that one reason for the failure of some trials may be that such doses of minocycline are too
low to be neuroprotective, pointing out that the typical effective dose in animal studies would be
equivalent to 3–7 g per day in humans.10 It would not be feasible or ethical to subject AD participants
to such very high doses of minocycline, but the Minocycline in Alzheimer’s Disease Efficacy (MADE)
trial includes a comparison of 400 mg per day with 200 mg per day to investigate the tolerability of
400 mg per day and whether or not the higher dose confers increased efficacy.
Alzheimer’s disease is a major public health issue and the imperative to discover and develop treatments
that can stop or at least delay disease progression is clear. Symptomatic AD treatments in the form of
cholinesterase inhibitors and memantine have been the mainstay of current treatment for > 10 years
but do not slow progression of the disease. With a more detailed understanding of the basic biology of
the AD process, a wide range of cellular and animal model systems have been developed within which
several candidate disease-modifying treatments appear promising, though no such agent has performed
successfully in Phase III trials.36,37 Unfortunately, the development of treatments for AD is a complex and
difficult process. The slowness of the neurodegenerative process and the substantial difficulties involved
in demonstrating that the process has been changed by treatment are major contributors to this problem.
Minocycline was arguably the most promising off-patent candidate for AD modification that was not yet
in trials, and it was cheap and well tolerated. The time was known to be right for an adequately powered
clinical trial, conducted for a sufficiently long period to demonstrate efficacy on simple cognitive and
functional outcomes. The results, even if clearly negative, could be expected to move the field on a
significant degree.
Based on this wealth of preclinical research suggesting neuroprotection, this trial investigated whether
or not minocycline slows decline in cognitive and functional ability in people with mild AD over a 2-year
treatment period. The safety and tolerability of minocycline was also compared at doses of 200 mg and
400 mg per day.
INTRODUCTION
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Chapter 2 Methods
Objectives
The MADE study was a multicentre randomised controlled trial with the following objectives.
The primary objective was to determine whether or not minocycline is superior to placebo in slowing
the disease course of early AD, over a 2-year period, as measured by rate of decline in cognition
[as measured by the standardised Mini Mental State Examination (sMMSE)] and function [as measured
by the Bristol Activities of Daily Living Scale (BADLS)].
The secondary objectives of the MADE trial were to:
l compare the safety and tolerability of minocycline at doses of 400 and 200 mg per day
l determine whether or not 400 mg per day offers superior neuroprotection to 200 mg per day
l investigate associated risks of side effects and serious adverse events
l estimate the magnitude of any statistically significant positive treatment effects on cognitive and
functional decline and, thereby, inform the design and powering of a future Phase III trial of
definitive clinical effectiveness within the NHS.
Trial design
The MADE study was a multicentre, randomised, double-blind trial for patients with very mild AD.
It had a semifactorial design in which participants were allocated to one of three treatment arms:
l arm 1 – 400 mg per day of minocycline
l arm 2 – 200 mg per day of minocycline
l arm 3 – placebo.
Trial treatment continued for a period of up to 2 years.
A summary of all changes to the protocol, including amendments to the inclusion/exclusion criteria and
safety monitoring protocol, are presented in Appendix 1.
Ethics approval and research governance
The MADE trial was conducted in accordance with the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human Use – Good Clinical Practice
guidelines and the Declaration of Helsinki.38 The study protocol, patient and caregiver information
sheets and informed consent forms were approved by East of England/Essex Research Ethics Committee
(REC; reference number 13/EE/0063) and the Medicines and Healthcare Products Regulatory Agency
(reference number 14523/0246/001-0005). Ethics approval for the trial was given by the National Research
Ethics Service (NRES) Committee East of England on 1 May 2013 (reference number 13/EE/0063). Local
REC approval and the appropriate site-specific assessments were obtained from each of the 32 participating
NHS trusts (see Acknowledgements for a full list of participating trusts). The trial was registered with
the International Standard Randomised Controlled Trial Register (ISRCTN) with the reference number
ISRCTN16105064. Trial conduct was overseen by independent Data Monitoring and Trial Steering
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Committees. The protocol for the trial can be found on the National Institute for Health Research
(NIHR)’s management information system portal.
Outcomes
Standardised Mini Mental State Examination
The first primary outcome measure was the sMMSE,39,40 a widely used clinician-rated instrument for
assessing cognition. Scores range from 0 to 30 points, with higher scores indicating better cognitive
function.41 The original Mini Mental State Examination (MMSE) was designed as a brief test to detect
organic brain disease and quantify the degree of cognitive impairment. It is still probably the most
widely used cognitive test in the world42 and has good psychometric properties.43 The sMMSE was
developed to provide raters with explicit guidelines for administration and scoring, with the aim of
improving the reliability of the instrument. The sMMSE differs from the MMSE in four main areas:
serial sevens are omitted, the order of the time orientation questions is changed, for all questions a
response time limit is imposed and for each item unambiguous scoring rules are given. The sMMSE score
is considered to be of clinical relevance, with the minimum clinically important difference estimated
to be 1.4 points.44 The sMMSE has been shown to be sensitive to the effects of anti-dementia drug
treatment in previous AD clinical trials.45–47
Standardised Mini Mental State Examination data were collected at screening and at 6, 12, 18 and
24 months.
Bristol Activities of Daily Living Scale
The second outcome measure is the BADLS,48 used to assess functional ability (activities of daily living).
Scores range from 0 to 60 points, with higher scores indicating greater impairment. The BADLS was
specifically designed for use with dementia patients living in the community and participating in clinical
trials. The BADLS is sensitive to change, correlates well with economic outcomes and, despite being a
carer-rated instrument, appears to have good test–retest reliability. The levels of disability between
which the scale aims to discriminate were also carer generated, giving some perspective on the value
of change, with the minimum clinically important difference estimated to be 3.5 points.44 The BADLS
has also been shown to be sensitive to change across a wide range of functional disability in previous
AD clinical trials.45,49
Bristol Activities of Daily Living Scale data were collected at baseline and at 6, 12, 18 and 24 months.
Participants
Patients were identified from NHS Memory Services at 32 university and general mental health trusts
in England and Scotland. The inclusion and exclusion criteria used to select patients are detailed in the
next two sections.
Inclusion criteria
The inclusion criteria include patients:
l with a diagnosis of possible or probable AD by National Institute on Aging–Alzheimer’s Association’s
(NIA–AA) criteria50
l with a sMMSE score of > 23 points, with no upper limit
l giving informed consent to participate
l aged ≥ 50 years
l who have a potential informant who will assist in the administration of the BADLS.
METHODS
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Exclusion criteria
The exclusion criteria include patients:
l with a known allergy to tetracycline antibiotics
l of childbearing potential, that is, female patients who have not been surgically sterile (via hysterectomy,
bilateral salpingectomy/oophorectomy) for a minimum of 6 months or undergone bilateral tubal
occlusion/ligation at least 6 months prior or been postmenopausal for at least 1 year
l who have an uncontrolled serious concomitant illness
l who have a known chronic kidney disease stages 3b–5
l with moderate liver disease (based on the Child–Pugh Classification for Severity of Liver Disease)
l with abnormal serum chemistry laboratory values at screening, which are deemed to be clinically
relevant by the chief investigator
l who withhold consent for the study team to inform his/her general practitioner (GP)
l having systemic lupus erythematosus (SLE)
l participating in another clinical trial of an investigational medicinal product (IMP) in the previous
28 days.41
Recruitment procedure
Patients with very mild (as defined by a sMMSE score of > 23 points) AD (as defined by NIA–AA
criteria50) were identified from memory services, both within the participating NHS trusts (see below
for a comprehensive list of all participating NHS sites) where the principal investigators practised and
within the network of memory services supported by the Dementias and Neurodegenerative Diseases
Research Network (DeNDRoN). Potentially eligible patients were approached by a clinician who
knew them and were provided with an opportunity to hear more about research. The Join Dementia
Research recruitment tool was also used. Those patients interested met with a member of the research
team, who provided further information about the study. Potentially interested individuals were given
an opportunity to review the information, ask questions over the telephone and arrange a date for
interview. Written informed consent was obtained prior to commencing the screening assessment for
the trial and after the individuals had received the information sheet.
Screening
The diagnosis and provisional eligibility for the study was first confirmed using the inclusion/exclusion
criteria listed in Inclusion criteria and Exclusion criteria. The sMMSE was performed and this score was
also used as the baseline value. Blood was taken for full blood count and biochemical profile analysis.
The screening blood analysis results and concomitant medicines were reviewed and recorded to
confirm eligibility before randomisation.
Trial treatment
Trial treatment consisted of oral minocycline modified-release (MR) capsules or identically appearing
placebo packed into treatment cartons sufficient for 13 weeks’ treatment (with a small overage).
The dosing regimens for the three treatment arms were:
l arm 1 – minocycline (400 mg): two MR 100-mg capsules of minocycline in the morning and two MR
100-mg capsules in the evening
l arm 2 – minocycline (200 mg): one MR 100-mg capsule of minocycline plus one minocycline placebo
capsule in the morning and one MR 100-mg capsule of minocycline plus one minocycline placebo
capsule in the evening
l arm 3 – placebo minocycline: two minocycline placebo capsules in the morning and two placebo
minocycline capsules in the evening.
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Treatment packs were supplied on a 3-monthly basis for a total treatment duration of 24 months.
Participants, their carers, prescribing clinicians, outcome assessors and all MADE trial staff (except
statisticians) were masked to trial arm assignment.
Treatment preparation
Modepharma Ltd (Beckenham, UK) was responsible for arranging the IMP’s manufacture, as well
as project management and assistance relating to the IMP for the trial, including preparation of the
IMP Dossier (IMPD). The actual manufacturing of placebo, all IMP packaging and labelling, and final
qualified person (QP) release of the IMPs were undertaken by Piramal Healthcare UK Ltd (licence
number 29595; Morpeth, UK).
Acnamino™ (Dexel®-Pharma Ltd, Daventry, UK) MR 100-mg capsules were used as the active treatment.
These capsules were procured and supplied to Piramal Healthcare for IMP packaging by Modepharma.
Acnamino MR 100-mg capsules are hard gelatin capsules each containing one pink film-coated tablet
and one peach enteric-coated tablet. Each capsule contained 100mg of the active substance minocycline
as minocycline hydrochloride. Placebo tablet intermediates were made using similar tablet tooling and
film-coating colour to the tablets in the active Acnamino MR 100-mg capsule. The blinding of the placebo
product was achieved by using the same capsule size and similar gelatin capsule body and cap colours as
the Acnamino MR 100-mg capsule. Placebo blister strips and patient treatment packs matched those of
the active substance and were labelled in the same way.
Packaging and labelling
Both active and placebo IMPs were packaged under QP control by Piramal Healthcare UK Ltd. Capsules
were packed in blister strips of 27 capsules, with a colour-coded Annex 13-compliant label.51 Seven blister
strips (i.e. 189 capsules) were placed in a carton, each with its own individual randomisation number
(or treatment pack number) and colour-coded Annex 13-compliant label. Patients were given two cartons,
each containing seven blister strips, at randomisation and every 3 months subsequently. Two cartons made
up a 3-month (13-week) supply. Patients were directed to take one capsule from one carton and one capsule
from the other carton every morning and every evening. As the capsules and blisters looked the same,
for patients’ ease, the labels used on the first and second cartons (and blisters) had two different colours.
Storage and dispensing
Batches of treatment packs were distributed to participating trial pharmacies by Polar Speed (Leighton
Buzzard, UK). Drug supplies were kept in a secure, limited-access storage area, in their original
packaging and under the authorised storage conditions for the Acnamino MR 100-mg capsules, and
instructions stated ‘Store in the original package’. Trial participants were advised to store medication at
ambient temperature and out of the reach of children. All unused medication was destroyed by the site
pharmacy. Receipt, usage and destruction was monitored and documented throughout the trial on the
respective forms. Account was given for discrepancies.
Unblinding
Investigators and patients remained blinded to the treatment allocation throughout the trial.
Unblinding was not normally necessary as serious side effects were dealt with on the assumption that
the patient was on active minocycline treatment. Study medication was omitted rather than unblinded.
If considered urgently necessary for patient management, a 24-hour unblinding service was available
(personal communication).
METHODS
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Concomitant medication
Patients could be randomised into the MADE study while taking a cholinesterase inhibitor or memantine.
Cholinesterase inhibitors and memantine could also be commenced or discontinued during the course of
the study at the discretion of the responsible consultant.
Other concomitant medications that may interact with minocycline [listed in the summary of product
characteristics (SmPC) for minocycline and summarised below] were recorded at each visit and the
prescriber informed:
l angiotensin-converting enzyme (ACE) inhibitors – absorption of minocycline decreased by
quinapril tablets
l antacids, adsorbents and vitamin/mineral supplements – absorption of minocycline is impaired by
the concomitant administration of antacids, iron, calcium, aluminium, magnesium and zinc salts
(interactions with specified salts, antacids and kaolin) unless taken 3 hours apart; dosages should be
maximally separated
l antibacterials – minocycline can decrease the effectiveness of penicillins
l anticoagulants – tetracyclines depress plasma prothrombin activity and reduced dosages of
concomitant anticoagulants may be necessary
l diuretics – may aggravate nephrotoxicity by volume depletion
l ergotamine and ergometrine – increased risk of ergotism
l retinoids – administration of isotretinoin should be avoided shortly before, during and shortly after
minocycline therapy as the combined administration of the two drugs increases the risk of benign
intracranial hypertension
l ulcer-healing drugs – absorption of minocycline is decreased by sucralfate and bismuth salts.
Side effects
If side effects were reported their significance was discussed with the study doctor. Depending on
severity, participants were asked to continue with the study drug if possible and a review by the
study doctor arranged in 2 weeks. If, at the time of the review, the side effects were severe enough to
warrant withdrawal from the study, participants were advised to omit the morning dose and a further
review arranged in 2 weeks. If side effects persisted, participants were advised to take a temporary
(e.g. 2-week) break from IMP treatment and were reminded to restart once the symptoms resolved.
If side effects persisted, then participants were advised to stop taking the study drug.
Treatment compliance
Treatment compliance was monitored by capsule count at the 6-, 12-, 18- and 24-month visits and
monitored over the telephone at week 2, and then at months 3, 9, 15 and 21. Participants were asked
to bring any unused study medication at each follow-up visit and at the end of the trial. Unused study
medication was obtained from the carer at these assessments. The local principal investigator (PI) or
research worker kept a log of study medication returns, return date and amount of study medication
returned and entered the information on the case report form. Once returned medication had been
logged, it was destroyed by the local pharmacy. Carers were also questioned regarding study drug
compliance at all interim assessments. The study-specific prescriptions were maintained in the
pharmacy file for audit purposes.
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Drug accountability
The study drug was dispensed by the local site pharmacy and full accountability of dispensing by the
pharmacy and of returns (at each face-to-face visit) was undertaken by the PI or one of the research
team. The pharmacy departments at each site maintained a study medication dispensing log, which
included date dispensed, batch number, expiry date and number of capsules dispensed. In addition, the
unique code numbers assigned to the treatment pack and trial patients were recorded. The study-specific
prescriptions were maintained in the pharmacy file for audit purposes. Once the unused or partially used
drug supplies were verified they were destroyed by the local pharmacy.
Assessments
Screening and randomisation were performed prior to the assessments described below.
Baseline
The baseline assessment took place within 28 days of screening. The BADLS was then administered to
complete the primary outcome assessments. Three months’ study drug was supplied via the trial pharmacy.
2-week assessment
A telephone assessment of safety, tolerability, compliance and concomitant medicines was made.
3-, 9-, 15- and 21-month assessments
An assessment of safety, tolerability, compliance and concomitant medicines was made. Blood was taken
for analysis at the clinic or patient’s home. Three months’ study drug was supplied via the trial pharmacy.
6-, 12- and 18-month assessments
Compliance and safety was assessed and concomitant medicines recorded. Primary outcomes were
administered and blood was be taken for analysis at the clinic or patient’s home. Three months’ study
drug was supplied via the trial pharmacy.
24-month assessment
Primary outcomes were administered. Compliance and safety were assessed and concomitant medicines
recorded. See Table 1 for further details on the administration of the study assessments.
Safety and tolerability
Our secondary objectives focused on the safety and tolerability of the treatment and, therefore, data on
safety parameters [including blood monitoring of haematological, renal and hepatic function as well as
documentation of skin reactions, gastrointestinal and neurological symptoms and concurrent infections
(i.e. bacterial enteritis, Clostridium difficile and orogenital candidiasis)] were also assessed and recorded
every 3 months. To monitor renal function, the Modification of Diet in Renal Disease (MDRD) formula
was used to calculate the estimated glomerular filtration rate (eGFR) at baseline and changes in creatinine
levels were used to monitor renal function post baseline. In particular, the following guidelines (which
were generated with approval by the Trial Management Group and in consultation with renal physicians)
were used:
Any patient with a follow-up creatinine [level] of ≥ 25% and < 50% higher than their baseline value can
remain on treatment, but will have a repeat blood sample in 2–3 weeks. If creatinine [levels] remain the
same or higher, then a further check will be required. Any patient with a follow-up creatinine [level] of
≥ 50% higher than baseline can remain on treatment but will have a repeat blood sample within 10 days.
If creatinine [levels] remain the same or higher, then study treatment will be stopped (unless an obvious
alternative cause is identified, e.g. NSAID [non-steroidal anti-inflammatory drug] use, other illness).
METHODS
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Randomisation and blinding
Once informed consent had been given, and baseline assessments completed, participants were randomly
allocated, using a centralised randomisation service, to one of three trial arms: 400 mg of minocycline,
200 mg of minocycline or placebo. Treatment packs were allocated centrally by the MADE study office.
The minimised randomisation procedure aimed to balance treatment allocation overall, and by four
stratification variables: centre, duration of symptoms prior to randomisation (< 6 months, ≥ 6 months),
baseline sMMSE score (24–26, 27–30 points) and age (< 65, 65–74, ≥ 75 years). Participants were
enrolled by their clinicians or appropriately trained clinical study officers or research nurses. These
staff also administered the outcome assessments. Patients, caregivers, clinicians, outcome assessors
and investigators were blinded to treatment allocation.
The person randomising participants completed the MADE randomisation form and had to answer
a set of prespecified questions over the telephone. Alternatively, completed randomisation forms
were faxed – or scanned and e-mailed – to the MADE randomisation service, which provided a
call-back service with a treatment allocation. After all the necessary details had been provided, a
MADE patient trial number was assigned and two treatment pack numbers were allocated. Allocated
treatment packs of 400 mg per day of minocycline, 200 mg per day of minocycline or matching placebo
were dispensed to patients via a local pharmacy and/or researcher.
TABLE 1 Study time–event chart
Event
Time point
Screening Baseline
Week
2
Month
3
Month
6
Month
9
Month
12
Month
15
Month
18
Month
21
Month
24
Diagnosis **
Inclusion **
Exclusion **
Concomitant
medicines
** * ** ** * ** * ** * **
Consent **
Random **
sMMSE ** ** ** ** **
BADLS ** ** ** ** **
Dispense ** ** ** * ** * ** *
Compliance * * ** * ** * ** * **
Safety check * * ** * ** * ** * **
FBC/
biochemistry
** ** ** ** ** ** ** **
FBC, full blood count.
Notes
Assessments marked with two asterisks (**) represent visits, whereas those marked with one asterisk (*) could be
conducted over the telephone. All visits have a permissible window of ± 7 days for telephone calls and ± 14 days for
face-to-face visits.
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Ethics considerations
Any neuroprotective benefit from minocycline is likely to outweigh the risks. Minocycline is routinely used
at doses of 200 mg per day in the long-term treatment of acne and is considered safe in this indication.31
Rare side effects include acute renal failure, irreversible skin pigmentation and, very rarely, SLE.
The trial applied for multicentre research ethics approval and local research governance approval for
the studies. The study personnel, co-investigators and collaborators [the management group and
independent Trial Steering Committee (TSC)] ensured that the study was conducted within appropriate
NHS and professional ethics guidelines. Information was kept strictly confidential and held in accordance
with the Data Protection Act 1998.52 Data are held on a secure database on a password-protected
university computer. Access to data was restricted to the research team.
Participation in the MADE trial carried only a 1 in 3 risk of randomisation to placebo and patients did
not have to forgo treatment with a cholinesterase inhibitor or memantine if their responsible clinician
considered that they would benefit from such treatment.
Potentially eligible patients were approached by a clinician who knows them, and given the opportunity
to hear more about research activities. The study was also advertised directly to patients (via posters,
leaflets, etc.). Those individuals who were interested in learning more about research were referred to
a member of the research team, who provided an information sheet with full study details, including
possible benefits and risks. The potentially eligible patients were offered the opportunity to ask
questions and discuss any queries with the carer/relative/doctor and make a date for the eligibility
interview. Interested patients were sent the information sheet with the invitation to screening and
written informed consent obtained prior to commencing the screening assessment.
All researchers were trained in gaining informed consent through DeNDRoN or the Mental Health
Research Network training course. NRES guidance on the content and format of patient information
and consent documentation was followed. Consumer representatives were involved to ensure that
these documents and all other written trial materials were fit for purpose. Information about the study
was mailed to potential participants and their caregivers.
The main potential ethics issue in dementia trials is that the disease may interfere with an individual’s
ability to give informed consent. Because the trial was studying people with mild dementia, most of the
participants had capacity to give informed consent for their involvement. Consequently, fully informed
written consent was obtained from patients entering the MADE study. However, as patients remained
in the study for up to 2 years it was likely that some may have lost capacity over this period. Patients
were therefore also asked what they would want to happen in the event of them losing capacity during
the course of the study. These patients were given the option of either withdrawing at this point or a
decision being made on their behalf by their personal legal representative in line with the Medicines
for Human Use (Clinical Trials) Regulations 2004.53 This person was usually the patient’s main carer,
who would have the best knowledge of the individual’s attitudes and stated preference to research
and, consequently, was best placed to judge whether or not they would have wished to continue if they
had capacity. In this situation the patient’s agreement to participate was still obtained to their best level
of understanding and they did not remain in the study if they refused or showed significant distress.
Patient and public involvement
The study ensured that patients, carers and members of the general public were closely involved in
the trial. During the design of the trial all relevant documentation, including participant information
sheets and consent forms, were reviewed by our patient and public involvement (PPI) representatives.
A representative was invited from the Alzheimer’s Society to sit on the TSC and they were involved
METHODS
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in all ongoing trial matters including review of progress, group meetings, review of results and
dissemination stages.
Statistical considerations
The study aimed to randomise 560 participants in a semifactorial (i.e. 2 x 1) design, that is, 1 : 1 : 1
between minocycline (400 or 200 mg) and placebo. Based on previous studies, it was estimated that
24-month assessments would be available on at least 80% of surviving participants (i.e. ≈ 390), which
would provide 90% power at a p-value of < 0.05 to detect a small to moderate [0.35 standard deviation
(SD)] effect size for minocycline (any dose) compared with placebo on the primary outcome measures.
With outcome assessments on 130 patients allocated 400 mg of minocycline and 130 allocated 200 mg
of minocycline, the study would have 80% power at a p-value of < 0.05 to detect a 0.35 SD treatment
effect of 400 mg compared with 200 mg of minocycline at 24 months.
Only participants who received at least one capsule of the study treatment drug or placebo were to be
included in the analyses of primary and secondary outcomes. The primary analyses of the effect of
minocycline on rate of decline of sMMSE and BADLS scores, and subgroup analyses, used repeated
measures regression methods, adjusted for baseline scores. These analyses use all available assessment
data to maximise statistical power to detect any differences between treatments, and to minimise the
impact of missing outcome data. For both primary outcomes, the difference in the rate of decline
between minocycline (any dose) and placebo, and between patients allocated 400 mg and 200 mg of
minocycline, was compared using a time-by-treatment interaction test, with time modelled as a
continuous variable. Comparisons of time on trial medication over the 24-month follow-up period split
by treatment arms are displayed in Kaplan–Meier curves, with statistical significance determined by
log-rank tests. Participants who died were censored at the last assessment time point before death.
Reasons for stopping trial medication and adverse events are tabulated by treatment arm. The study
used SAS® software version 9.3 (SAS Institute Inc., Cary, NC, USA) for all statistical analyses. The
independent data monitoring committee and REC reviewed the unblinded accumulating data and the
safety of patients in the study at approximately yearly intervals.
Literature search
Prior to analysing the trial results, a literature search was carried out in 2018 to assess whether or
not minocycline affects disease progression in AD, but no relevant studies were found at this stage
(see Appendix 2, Table 6).
DOI: 10.3310/eme07020 Efficacy and Mechanism Evaluation 2020 Vol. 7 No. 2
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Howard et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
11

Chapter 3 Results
Between 23 May 2014 and 14 April 2016, 554 participants were entered from 32 NHS memoryservices in England and Scotland. Ten patients did not start trial medication and, as prespecified in
the protocol, were excluded from all analyses (Figure 1); one participant had been allocated to 400 mg
of minocycline, four to 200 mg of minocycline and five to placebo. Baseline characteristics of the 544
eligible participants were well balanced across the three treatment trial arms (Table 2).
The mean age of participants was 74.3 years, 57% (303/544) of whom were male and 84% (455/544)
of whom were living with a spouse, partner or relative. The average duration of symptoms was 24 months
and the average sMMSE score at baseline was 26.4 points.
The sMMSE assessments were obtained for 542 (99.6%) of the 544 participants at baseline, 498 (92%)
of the 544 participants at 6 months, 453 (84%) of the 537 participants at 12 months, 420 (80%) of the
528 participants at 18 months, and 403 (78%) of the 517 participants at 24 months (see Appendix 4,
Table 8). There were fewer BADLS than sMMSE assessments, because BADLS assessments are not
valid for participants in residential care.
Minocycline at a daily dose of 400 mg was poorly tolerated by participants, with just 29% (53/184) of
those allocated 400 mg of minocycline completing 2 years of treatment, significantly fewer participants
than in the 200 mg of minocycline (62%; 112/181) or placebo arm (64%; 114/179) (p < 0.0001; see
Figures 1 and 7). By contrast, 200 mg of minocycline was well tolerated by participants, with similar
discontinuation rates with 200 mg of minocycline and placebo (p = 0.56). When reasons for stopping
trial treatment were compared (Table 3), more participants allocated to minocycline than to placebo
stopped because of gastrointestinal symptoms (p = 0.0008), dermatological side effects (p = 0.02) and
dizziness (p = 0.01).
As a consequence of the higher treatment withdrawal rate, fewer assessments were obtained for
the 400 mg of minocycline treatment arm than for the 200 mg of minocycline and placebo arms
(see Appendix 4, Table 8). For sMMSE assessments at 24 months, 68% of assessments (119 of the
174 expected) were received for the 400 mg of minocycline arm, 82% (144/176) for the 200 mg of
minocycline arm and 84% (140/167) for the placebo arm. Return rates for BADLS assessments were
similarly lower for the 400 mg of minocycline arm than for the 200 mg of minocycline and placebo
arms (see Appendix 4, Table 8).
The change from baseline in sMMSE scores over time, with standard error bars, is shown in Figure 2.
There was an average 4.1-point reduction in the combined minocycline arms compared with a 4.3-point
reduction in the placebo arm over the 24-month study period (p = 0.90). The reduction in sMMSE score
in the 400 mg of minocycline arm over 24 months was less than that observed in the 200 mg of
minocycline arm (i.e. 3.3 vs. 4.7 points), but this difference was not significant (p = 0.08).
Likewise, the worsening of BADLS scores over 24 months was similar in all treatment arms: 5.7, 6.6 and
6.2 points in the 400 mg of minocycline, 200 mg of minocycline and placebo trial arms, respectively. There
were no significant differences in BADLS scores between participants allocated minocycline and those
allocated to the placebo arm (p = 0.57) or between those participants allocated 400 mg of minocycline
and those allocated 200 mg of minocycline (p = 0.77; Figure 3).
To assess how the higher number of missing outcome assessments in the 400 mg of minocycline
treatment arm than in the 200 mg of minocycline or placebo arms (see Appendix 4, Table 8) might
have affected outcome comparisons, various sensitivity analyses were run to investigate potential
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Assigned 400 mg of
minocycline
(n = 184)
Discontinued treatment
(n = 64)
Discontinued treatment
(n = 19)
19 discontinued treatment,
2 died (+ 1 death but
stopped previously)
26 discontinued treatment,
1 died (+ 6 deaths but
stopped previously)
Completed 3 months
(n = 120)
3 months
6 months
12 months
24 months
Completed 6 months
(n = 101)
Completed 12 months
(n = 81)
Completed IMP
(n = 53)
Assigned 200 mg of
minocycline
(n = 181)
Discontinued treatment
(n = 25)
Discontinued treatment
(n = 5)
19 discontinued treatment,
1 died
22 discontinued treatment,
1 died (+ 3 deaths but
stopped previously)
Completed 3 months
(n = 156)
Completed 6 months
(n = 151)
Completed 12 months
(n = 135)
Completed IMP
(n = 112)
Patients randomised
(n = 544)
Patients allocated treatment pack
(n = 554)
Assigned placebo
(n = 179)
Discontinued treatment
(n = 19)
Discontinued treatment
(n = 8)
15 discontinued treatment,
(+ 3 deaths but
stopped previously)
Patients who never started trial medication
(one patient died before month 9)
(n = 10)
• 1 in 400 mg of minocycline
• 4 in 200 mg of minocycline
• 5 in placebo
18 discontinued treatment,
5 died (+ 4 deaths but
stopped previously)
Completed 3 months
(n = 160)
Completed 6 months
(n = 152)
Completed 12 months
(n = 137)
Completed IMP
(n = 114)
FIGURE 1 Flow chart of participants through the trial.
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TABLE 2 Baseline characteristics, by treatment allocation, for the 544 eligible patients
Characteristic
Treatment arm
400mg of minocycline
(N= 184)
200mg of minocycline
(N= 181)
Placebo
(N= 179)
Age (years)
< 65, n (%) 22 (12) 22 (12) 21 (12)
65–74, n (%) 68 (37) 66 (36) 66 (37)
≥ 75, n (%) 94 (51) 93 (51) 92 (51)
Mean (SD) 74.3 (8.0) 74.1 (8.4) 74.6 (8.1)
Gender, n (%)
Male 104 (57) 100 (55) 99 (55)
Female 80 (43) 81 (45) 80 (45)
Home circumstance, n (%)
Living with spouse/partner/relative 153 (83) 153 (85) 149 (83)
Alone 31 (17) 28 (15) 29 (16)
Duration of symptoms
< 6 months, n (%) 20 (11) 20 (11) 20 (11)
≥ 6 months, n (%) 164 (89) 161 (89) 159 (89)
Mean (SD) 23.5 (18.3) 23.1 (17.8) 24.2 (18.0)
sMMSE score (points)
24–26, n (%) 100 (54) 97 (54) 96 (54)
27–30, n (%) 84 (46) 84 (46) 83 (46)
Mean score (SD) 26.4 (1.9) 26.5 (1.9) 26.4 (1.8)
TABLE 3 Reasons for stopping treatment by treatment allocation
Reasons for stopping
Treatment arm (n)
Total
(n)
Minocycline vs.
placebo p-value
400mg of
minocycline
(N= 184)
200mg of
minocycline
(N= 181)
Placebo
(N= 179)
GI symptoms 42 15 10 67 0.00080
Dizziness 14 3 1 18 0.01000
Dermatological symptoms 10 5 1 16 0.02000
Haematological 5 3 1 9 0.16000
Impaired renal function 2 5 4 11 0.81000
Infection 1 2 2 5 0.74000
Shortness of breath 6 0 0 6 0.08000
Worsening dementia 1 3 3 7 0.57000
Depression or anxiety 4 2 2 8 0.63000
continued
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bias from non-random dropout. In particular, there were 41 participants who had a baseline sMMSE
score but no further assessments, so did not contribute any information to the primary analysis
(see Appendix 4, Figure 8). Those participants who discontinue treatment in AD trials are often atypical,
usually having worse cognitive and functional ability than those who continue.20 This is evident from
the scores of the 41 participants with a 6-month sMMSE score but no later assessments.
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Month of assessment
Any dose of minocycline vs. placebo; p = 0.90
400 mg vs. 200 mg of minocycline; p = 0.08
Treatment arm
400 mg of minocycline
200 mg of minocycline
Placebo
FIGURE 2 Change in sMMSE scores: baseline to 24 months’ follow-up. The graph shows change in mean sMMSE score
with standard errors; baseline scores are set to zero; p-values are from tests of the time-by-treatment interaction from
repeated measures analyses.
TABLE 3 Reasons for stopping treatment by treatment allocation (continued )
Reasons for stopping
Treatment arm (n)
Total
(n)
Minocycline vs.
placebo p-value
400mg of
minocycline
(N= 184)
200mg of
minocycline
(N= 181)
Placebo
(N= 179)
Joint or muscle pain 2 0 2 4 0.47000
Concomitant disease/illness 9 6 7 22 0.91000
General deterioration in physical health 2 0 2 4 0.47000
Unknown 1 0 0 1 0.48000
Unspecified side effect 5 2 7 14 0.17000
Patient or carer choice 23 21 18 62 0.49000
Total 127 67 60 254 0.00002
GI, gastrointestinal.
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In total, there were 252 reported serious adverse events (SAEs), with the most common categories
being neuropsychiatric and cardiocirculatory. The number of SAEs was somewhat higher in the placebo
arm than in the 400- and 200-mg minocycline treatment arms (Table 4). Given that gastrointestinal
symptoms were the main reason for stopping trial treatment, it is reassuring that the numbers of
gastrointestinal SAEs in the minocycline arms were low, and no higher than in the placebo arm. Similarly,
though more skin-related toxicities, particularly pigmentation, were reported with minocycline than with
placebo [36% (130/365) vs. 21% (38/179); p = 0.0007], few participants stopped trial treatment because
of such toxicities (see Table 3) and only six skin toxicities were considered severe (three in participants
allocated to any dose of minocycline and three in participants to placebo; see Appendix 4, Table 9). There
were no differences in the numbers of participants stopping treatment because of impaired renal
function, which had been a prior concern, nor in numbers of renal SAEs. Twenty-eight patients died
during the study: 10 allocated to the 400-mg minocycline treatment arm, six to the 200-mg minocycline
treatment arm and 12 to the placebo arm (see Appendix 4, Table 10 and Figure 11a). Fifteen of these 28
patients had stopped trial treatment prior to dying. One additional patient died without starting trial
treatment. Rates of care home admission were low in this mild AD population, with no difference in
numbers between trial arms (see Appendix 4, Figures 11b and 11c).
The average decline in sMMSE score from baseline to 6 months in this subset of patients (i.e. those
patients without any post-baseline assessments) was 3.9 points, a rate of decline three times higher
than the 1.3-point average decline among the 498 patients who had a 6-month sMMSE assessment
and went on to complete later assessments. It seems likely, therefore, that those patients without any
post-baseline assessments, who do not contribute to the estimate of the rate of decline, also had a
worse than average decline in cognitive and functional ability.
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Any dose of minocycline vs. placebo: p = 0.57
400 mg  vs. 200 mg of minocycline: p = 0.77
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200 mg of minocycline
Placebo
FIGURE 3 Change in BADLS scores: baseline to 24 months’ follow-up. The graph shows change in mean BADLS scores
with standard errors; baseline scores are set to zero; p-values are from tests of the time-by-treatment interaction from
repeated measures analyses.
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To estimate what impact the missing outcome data from the 41 participants with no post-baseline
assessments might have had on the trial results, the study’s sensitivity analyses made two
different assumptions:
1. It was assumed that for the first 6 months the scores declined at a rate of 3.9 points (as did those
scores for participants who had a 6-month sMMSE but no further assessments) and then declined at
the average rate of 1.1 points every 6 months for the rest of the trial.
2. It was assumed that for patients who had no postbaseline assessments the scores declined at the
average rate of those participants with assessments, that is, 1.3 sMMSE points for the first 6 months
and then 1.1 points every 6 months subsequently.
The results from imputation methods 1 and 2 are shown in Appendix 4, Figures 9a and 9c. The results are
not qualitatively different from those of the primary analyses. The only borderline-significant (p = 0.06)
differences seen in these sensitivity analyses were between 400 and 200 mg of minocycline. However,
with 400 mg of minocycline a little better and 200 mg of minocycline a little worse than placebo, and no
difference between any dose of minocycline and placebo, this is probably a chance finding.
Because return rates for BADLS assessments were also lower for the 400 mg of minocycline arm than
the 200 mg of minocycline and placebo arms, similar sensitivity analyses were run. There were 39
participants with no BADLS assessment post baseline who did not contribute to the primary analysis.
Imputation method 1 assumed that their BADLS score worsened (i.e. increased) by 3.7 points over
the first 6 months and then by 1.9 points every 6 months for the rest of the trial. Method 2 assumed
that their BADLS score worsened by 1.5 points over the first 6 months and then by 1.9 points
subsequently. Because BADLS is valid only for community-resident patients, BADLS scores for those
who went into residential care were imputed only up until the last time point before moving into care.
TABLE 4 Serious adverse events by treatment allocation
SAE class
Treatment arm, counts of SAEs reported
Total counts of
SAEs reported
Minocycline vs.
placebo p-value
400mg of
minocycline
(n= 184)
200mg of
minocycline
(n= 181)
Placebo
(n= 179)
Gastrointestinal 3 8 10 21 0.1400
Respiratory 8 8 10 26 0.5400
Mechanical injury 6 11 13 30 0.2100
Endocrine and metabolic 2 1 9 12 0.0020
Cancer 12 3 11 26 0.0200
Haematological/thrombosis 3 1 2 6 0.9800
Dermatological 0 1 0 1 0.4800
Neuropsychiatric 10 13 16 39 0.2600
Cardiocirculatory 14 9 11 34 0.9400
Renal 3 2 2 7 0.4000
Infection 10 1 19 30 0.0003
Other 7 11 2 20 0.0300
Total 78 69 105 252 –
Differences were compared with the chi-squared test with associated p-values (two-sided).
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Results for imputation methods 1 and 2 are shown in Appendix 4, Figures 9b and 9d. Again, results were
not qualitatively different from those of the primary analyses of BADLS assessment scores.
To investigate whether or not the efficacy of minocycline varied by baseline characteristics, subgroup
analyses of change in sMMSE over 24 months for minocycline (any dose) versus placebo by duration of
symptoms, baseline sMMSE, age and gender were conducted (see Appendix 4, Figure 10). There were
no indications of any benefit from minocycline treatment in those participants with shorter or longer
durations of symptoms, lower or higher baseline sMMSE scores, or in men or women. There was a
borderline-significant (i.e. p = 0.04) trend towards greater efficacy in younger than older patients, but
this unanticipated finding could be a chance occurrence given the number of subgroup investigations.
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Chapter 4 Discussion
The MADE trial has shown that, in patients with mild AD, 24 months of minocycline treatment atthe doses tested does not delay the progress of cognitive or functional impairment, as measured
by the well-validated and widely used sMMSE and BADLS clinical rating scales. The trial has also
established that minocycline at a dose of 400 mg is poorly tolerated in this population, with fewer
than one-third of participants completing 24 months of treatment. By contrast, 200 mg per day
of minocycline is well tolerated, with participants allocated this treatment being no more likely to
withdraw from trial medication than those taking placebo.
The failure of minocycline to slow the progression of cognitive and functional decline in mild AD is
disappointing given the evidence suggesting that neuroinflammation is instrumental in AD progression,7
minocycline’s established anti-inflammatory and neuroprotective effects and the positive data from several
experimental animal models of AD.11–17 NSAIDs have similarly failed to slow disease progression in clinical
trials,54 despite long-term use being associated with a lower risk of developing AD in observational
studies55 and promising data from transgenic animal models.56 The study’s findings also parallel those of
clinical trials of minocycline in other neurodegenerative disorders in which, despite preclinical research
suggesting neuroprotection, minocycline worsened outcomes in ALS,25 had no effect in Huntington’s
disease57 and multiple system atrophy,58 had negative symptoms in schizophrenia59 and had only short-term
benefits in multiple sclerosis.60
Therefore, there could be three broad potential explanations for the negative results of this trial.
First, although there is good evidence for neuroinflammation in AD,7 this may be more a reaction to
pathology than an important driver of progressive neurodegeneration, particularly in patients who are
still at the mild stage of dementia. Second, even if neurodegeneration is accelerated by neuroinflammation,
minocycline at the doses administered in the MADE study may not have had sufficient activity against
these processes to show efficacy. Animal studies, from which much of the evidence for minocycline’s
activity as an anti-inflammatory and anti-AD agent has come, have generally used much higher doses of
minocycline than used in the MADE trial (i.e. typically equivalent to 3–7 g per day in humans)10 and, so, it
could be that trial participants were not exposed to a sufficiently high dose for efficacy. However, if doses
of 200–400mg per day are insufficient for neuroprotection, the difficulties with tolerability experienced
by participants allocated 400 mg of minocycline indicate that use of higher doses in this patient population
is not feasible.
Minocycline is potentially neuroprotective through several anti-inflammatory processes (suppression of
microglial proliferation and activation, reduced release of interleukins 1β and 6 and of tumour necrosis
factor alpha, decreased chemokine expression and decreased activity of metalloproteases) as well as
anti-apoptotic and anti-oxidant effects.11–17 A study of 15 patients with traumatic brain injury found
reduced microglial activation, as visualised with 11C-PBR28 positron emission tomography (PET),61
following 12 weeks of treatment with 200 mg of minocycline per day, indicating that the dose ranges
used in the MADE trial can have a measurable effect on anti-inflammatory targets. The relationship
between minocycline-sensitive microglial activation and neurodegeneration may, however, be
complicated. Minocycline treatment in the traumatic brain injury study61 was also associated with
increased plasma levels of neurofilament light, considered a marker of neurodegeneration. The faster
progression seen with minocycline in ALS25 also suggests that some activated microglia might have a
reparative function so that their inhibition could accelerate neurodegeneration. This study’s results do
not suggest that reduced microglial activation with minocycline worsens neurodegeneration in AD.
A third plausible explanation for the negative results of the MADE study could be that minocycline did
have some efficacy against progression of AD but treatment effects were too small to be detectable
in the trial. It is difficult to discount this possibility. The MADE trial was, however, powered to detect
minimal clinically important differences between minocycline and placebo, so smaller differences might
not be considered of clinical relevance.
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This pragmatic trial had a number of strengths. It was based in a broad network of academic and NHS
memory services and the wide eligibility criteria facilitated the recruitment of participants who were
representative of patients with very mild AD diagnosed within the NHS. Outcome measures were limited in
number, practical and easy to administer reliably by trial staff and chosen because any differences between
minocycline and placebo treatment would have unambiguous clinical relevance. The trial recruited to
target and was sufficiently large to detect a clinically meaningful treatment effect, and the trial arms
were well matched on potentially important variables at baseline. This streamlined trial design could
usefully be applied to test other putative disease-modifying therapies.
Potential limitations of the study include that biomarkers were not used to confirm AD diagnosis, because
these are not routinely available within the NHS and, therefore, there was no access to these data.
Nonetheless, no diagnoses were revised during the study and rates of decline were as expected in a
mild AD population. Compliance was also problematic, with few patients in the 400-mg arm completing
2 years of treatment and only moderate compliance in the 200-mg and placebo arms. A recommendation
to take trial medication once rather than twice daily in the event of perceived side effects helped
improve compliance but was introduced only late in the trial when the problem with 400-mg compliance
was identified.
Although the trial protocol specified that outcome assessments should be obtained irrespective of
treatment compliance, this could not always be achieved despite the vigorous efforts of the trial team.
Consequently, differential follow-up rates could have biased the study’s results. However, despite
the large number of treatment withdrawals in the 400-mg arm, and consequent loss to follow-up of
some participants, results were essentially unchanged in sensitivity analyses investigating potential bias
from missing data. Thus, the study’s conclusion that 2 years of minocycline treatment for patients with
mild AD does not result in any clinically meaningful difference in the rate of decline of cognitive and
functional ability is disappointing but robust.
DISCUSSION
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Cambridge, UK); Chris Fox (University of East Anglia, Norwich, UK); Naji Tabet (University of Sussex,
Brighton, UK); Gill Livingston (University College London, London, UK); Peter Bentham (Birmingham and
Solihull Mental Health NHS Foundation Trust, Birmingham, UK); Rupert McShane (University of Oxford,
Oxford, UK); Alistair Burns (University of Manchester, Manchester, UK); Craig Ritchie (University of
Edinburgh, Edinburgh, UK); Suzanne Reeves (University College London, London, UK); Simon Lovestone
(University of Oxford, Oxford, UK); Clive Ballard (University of Exeter, Exeter, UK); Wendy Noble (King’s
College London, London, UK); Gordon Wilcock (Nuffield Department of Clinical Neurosciences, University
of Oxford, Oxford, UK); and Richard Gray (NDPH, University of Oxford, Oxford, UK).
Data monitoring committee
Peter Crome (chairperson), Jeremy Brown and Sarah Walker.
Trial Steering Committee
Gordon Wilcock (chairperson), Peter Dyte, Declan McLoughlin, Rosie Bradley, Richard Gray and
Robert Howard.
Trial management
Olga Zubko, Rebecca Gathercole (King’s College, University of London, London, UK); Emma Harper,
Lynn Pank, Linda Kelly, Natalie Lam and Keith Anderson (NDPH, University of Oxford, Oxford, UK).
Trial monitoring
King’s Health Partner’s Clinical Trials Office (London, UK).
Pharmacist
Nigel Barnes.
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Participating centres and MADE Collaborative Group members
An asterisk (*) indicates PI at that centre.
Sadly, Rob Jones (†) and Selina Paul (‡) died unexpectedly during the course of the MADE trial.
Avon and Wiltshire Mental Health Partnership NHS Trust (number of patients, 20)
Rosalind Ward,* Hayley Dash, Joanna Morris-Bone, Catherine Roiz De S’a, Tanya Atapattu, Emma McNeill,
Peter Arthure and Aiste Baltramaityte.
Berkshire Healthcare NHS Foundation Trust (number of patients, 26)
Nicholas Woodthorpe* and Lynn Rigby.
Birmingham and Solihull Mental Health NHS Foundation Trust (number of patients, 31)
Peter Bentham,* Jane Dyer, Di Baines, Abdul Patel,* Jan Wright, Akram Ali and Nigel Barnes.
Black Country Partnership NHS Foundation Trust (number of patients, three)
Tarik Qassem,* Aparna Prasanna,* Joanne Sawyer, Neeti Gupta, Laura Lord, Aparna Prasanna,
Amy Shipman, Darren Weaver, Gurj Bhella, Danielle Cornford, Susan Horton, Tim Kingscote-Davies,
Amanda Nicklin, Carolyn Ogden and Sukvinder Sandhar.
Bradford District Care NHS Foundation Trust (number of patients, 10)
Anilkumar Pillai,* Deepa George, Alison Barraclough, John Hiley, Sarah Poll, Jyoti Rana, Gregor Russell,
Angus Sturrock, Sade Abiola, Jaspreet Sohal and Edward Sykes.
Cambridgeshire and Peterborough NHS Foundation Trust (number of patients, 23)
John O’Brien,* Siobhan Rust, Julie Philps, Annabel Price, Ben Underwood, Steven Albery, Lorraine Carter,
Rachel Wade, Lauren Dawson, Bernice Gregory, George Griffiths, Christopher Jenkins, Clare Mundell,
Christine Rowe and Sara Williamson.
Camden and Islington NHS Foundation Trust (number of patients, 16)
Gill Livingston,* Jonathan Flor Mary-Jo Doyle, Yvonne Foreshaw, Kate O’Connor, Selina Paul,‡
Poureya Aghakhani, Silvia Ceci and Adam Heffer.
Cornwall Partnership NHS Foundation Trust (number of patients, 15)
Vandana Mate,* Sharon Hudson, Suzanne Dean, Jackie Kerr, Joanna Ledger, Sadir Altaan,
Emma O’Shaughnessy, Linda Allsop, Carolyn Brodie, Kimberley Moore and Johanna Skewes.
Coventry and Warwickshire Partnership NHS Trust (number of patients, 16)
Demi Onalaja,* Emily Benson, Wendy Roughan and David Tait.
Cumbria Partnership NHS Foundation Trust (number of patients, 15)
Marisa Wray* and Yumna Masood.
Derbyshire Healthcare NHS Foundation Trust (number of patients, 23)
Simon Thacker,* Smita Saxena, John Sykes, Gemma Harrison, Audrey Williamson, Caroline Cheetham,
Graham Spencer, Victoria Baron, Russell Cooper, Megan Harman and Sandra Kimberlin.
Gloucestershire 2gether NHS Foundation Trust (number of patients, 11)
Tarun Kuruvilla,* Bethan Cartwright, Jenny Romer, Marelle Harvey.
Kent and Medway NHS and Social Care Partnership Trust (number of patients, 8)
Richard Brown,* Amy Hammond, Alison Welfare-Wilson, Vilma Gilis, Sam Manktelow and Agostina Secchi.
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Leeds and York Partnership NHS Foundation Trust (number of patients, 20)
Anna Green,* Lisa Hackney, Wendy Neil,* Aishia Perkis, Damian Reynolds, Jenny Sweetman,
Danielle Varley, Francesca Williams, Amanda Taffinder, Michael Dixon, David Braun and Lucy Allender.
Leicestershire Partnership NHS Trust (number of patients, 17)
Sarah Baillon, Latha Velayudhan,* Santanu Chakrabarti,* Sarah Thomason, Howard Fairey, Tom Pringle,
Robyn McAskill and Lynne Hartwell.
Lincolnshire Partnership NHS Foundation Trust (number of patients, six)
Ban Al-Kaissy,* Diane Brennan, Lizwi Nyathi, Vijayendra Waykar, Kerry Evans, Dimple Oza and
Aliya Turk Richard Lewis.
Manchester Mental Health and Social Care Trust (number of patients, 23)
Iracema Leroi,* Lewis Harpin, Alistair Burns, Christopher Broughton, Hannah Goldup, Sharon Hall,
Lewis Harpin, Adam Kennedy, Sally-Anne Heasman, Javier Torres Martin, Andrew Peers, Jane Smithies,
Maxine Syme and Michelle Thorpe.
NHS Ayrshire and Arran (number of patients, four)
Ajay Macharouthu,* Mark Wilson, Jacqui Kerr, Colin Grant, Elma Norwood, Alistair Rennie, Karen Greig
and Lynne McNeil.
Norfolk and Suffolk NHS Foundation Trust (number of patients, 15)
Judy Rubinsztein,* Vandana B Menon,* Chris Fox, Zoe Inman, Louise McCarthy, Juniper West,
Bonnie Teague, James Curtis, Valerie Dixon and Dennis Liew.
Northamptonshire Healthcare NHS Foundation Trust (number of patients, 15)
Paul Koranteng,* Kim Burke and Helen Reboul.
Northumberland, Tyne and Wear NHS Foundation Trust (number of patients, 22)
Robert Barber,* Victoria Hetherington, Jill Davison, Nichola Duffelen, Caroline Gerrard and
Matthew Haggerty.
Nottinghamshire Healthcare NHS Foundation Trust (number of patients, 21)
Rob Jones,*† Sujata Das,* David Trevor, Craig Beecroft, Kehinde Junaid, David Kelly, John Lawton and
Effie Pitsillides.
Oxford Health NHS Foundation Trust (number of patients, 26)
Rohan Van Der Putt,* Jenny McCleery,* Deborah Cooper, Jemima Hume, Justine Adams, Hazel Eaton,
Rupert McShane, Claire Merritt, Christine Parker, Gordon Wilcock, Marilyn Arnold, Ioana Fodor,
Orla Macdonald and David Sharma.
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust (number of patients, two)
Divya Tiwari,* Jo Bell, Chantel Cox, Owen David, Emma Gunter, Gail Hann, Becky Jupp,
Catherine Ovington, James Page, Andrew Williams, Rachel Bower, Alison Hogan and Sam Lloyd.
Southend University Hospital NHS Foundation Trust (number of patients, five)
John Whitear* and Paula Harman.
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South London and Maudsley NHS Foundation Trust (number of patients, 54)
Robert Howard,* Olga Zubko, Leeza Almedom, Lauren Armstrong, Ana Bajo, Rebecca Brendell,
Jack Cahill, Hannah Grocott, Siobhan Hurley, James Rackie, Arann Rowe, Clive Ballard, Jenny Bousfield,
Elizabeth Highton-Williamson, Zainab Al Noor, Suzanne Reeves, Melody Smith, Ola Dada, Martin Heasman,
Glynis Ivin, Ian Osborne, Sophie Ward and Michael Welds.
South Staffordshire and Shropshire Healthcare NHS Foundation Trust (number of patients, 33)
Ejaz Nazir,* Paula Dolby, Lucy Hamilton, Yvette Lycett, Andy Taylor, Ayesha Bangash, Liz Glaves,
Sarah Johnson, Susan Lavender, Prince Nwaubani, Richard Heys, Felicity Massey, Ruth Mills,
Allison Newman, Sacheev Patel, Lindsay Rose, Carla Silva, Mark Stallard, Tamir Latif, Farzad Khalkhali,
Sudhakar Anumanchi, Eva Kabir, Adnan Sharaf, Sajeev Kshemendran and Rashi Negi.
South West London and St George’s Mental Health NHS Trust (number of patients, nine)
Robert Lawrence,* Enitan Eboda, Ashes Howson, Mustabshira Qayyum, Philip Woodgate,
Laura Dalrymple, Jess Lee, Felicity Mayer, Carl Holvey and Aiste Navickaite.
St George’s University Hospitals NHS Foundation Trust (number of patients, 20)
Jeremy Isaacs,* Sally Goff, Servious Dube, Peter Garrard and Jennifer Tulloch.
Surrey and Borders Partnership NHS Foundation Trust (number of patients, 30)
Ramin Nilforooshan,* Ruth Charig, Jane Gregg, Caroline Khurana, Helen Adams, Jack Holland,
Brian Parsons, Emily Williams, Samantha Francis, Richard Johnson, Fiona Lockwood, Ailsa McKay
and Jane Wenham.
Sussex Partnership NHS Foundation Trust (number of patients, 12)
Naji Tabet,* Samuel Holden, Gail Chandler, Andrew Risbridger, Gail Chandler and Gus Fernandez.
West London Mental Health NHS Trust (number of patients, three)
Sarah Gregory, Merrie Manalo, Vanessa Raymont,* Bryan Corridan,* Craig Ritchie,* Tahira Arshad,
Sharon Linsell and Laura McKee.
Contributions of authors
Robert Howard (https://orcid.org/0000-0002-3071-2338), Richard Gray (https://orcid.org/
0000-0003-4440-574X), John O’Brien (https://orcid.org/0000-0002-0837-5080), Peter Bentham
(https://orcid.org/0000-0002-6443-3353), Simon Lovestone (https://orcid.org/0000-0003-0473-4565),
Alistair Burns (https://orcid.org/0000-0002-9837-0645) and Suzanne Reeves (https://orcid.org/0000-
0001-8053-7024) designed the trial.
Olga Zubko (https://orcid.org/0000-0002-3520-624X), Emma Harper (https://orcid.org/0000-0001-
5651-6258), Linda Kelly (https://orcid.org/0000-0003-1936-0842), Lynn Pank (https://orcid.org/
0000-0001-6398-6565), Robert Howard and Richard Gray ran the trial.
Rosie Bradley (https://orcid.org/0000-0002-0758-4905) and Richard Gray analysed the data.
Robert Howard, Peter Bentham, John O’Brien, Gill Livingston (https://orcid.org/0000-0001-6741-
5516), Ramin Nilforooshan (https://orcid.org/0000-0001-9801-183X) and Naji Tabet (https://orcid.
org/0000-0003-4629-6196) recruited participants.
Robert Howard, Olga Zubko, Rosie Bradley and Richard Gray wrote the initial paper draft.
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Chris Fox (https://orcid.org/0000-0001-9480-5704), Rupert McShane (https://orcid.org/0000-0002-
3272-5984), Craig Ritchie (https://orcid.org/0000-0002-6202-6906), Clive Ballard (https://orcid.org/
0000-0003-0022-5632), Wendy Noble (https://orcid.org/0000-0002-7898-4295) and Gordon Wilcock
(https://orcid.org/0000-0003-0163-3021) contributed to writing and reviewing the paper.
All authors contributed to writing the paper and assume responsibility for the accuracy and
completeness of the data and for the overall content and integrity of the paper.
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Appendix 1 Protocol changes
Table 5 is a summary of the changes made to the original MADE trial protocol, which havebeen approved by the REC and the Medicines and Healthcare products Regulatory Agency
(where relevant).
TABLE 5 Research Ethics Committee- and Medicines and Healthcare products Regulatory Agency-approved amendments
Change to protocol Date
Increased leeway window for final assessments from ± 14 days to ± 30 days 22 March 2018
Guidance on restarting IMP added, with participants able to restart IMP at any time after break 29 July 2016
End-of-study participant letter added 29 July 2016
End-of-study GP letter added 29 July 2016
Increase recruitment from 480 to 560 participants by March 2016 30 October 2015
Adding JDR as additional recruitment tool 21 January 2015
Inclusion criterion ‘severe liver disease’ modified to ‘moderate liver disease’ 4 February 2015
Added a trial leaflet 3 September 2014
Added a trial recruitment advertisement poster 3 September 2014
Added a GP letter of invitation 3 September 2014
Add inclusion criterion: participants must have a potential informant to assist with
administration of the BADLS assessment
9 January 2014
Exclusion criterion ‘Patients with creatinine clearance < 50ml/minute at screening, according to
the Cockcroft and Gault equation must be excluded’ was added
7 August 2014
Exclusion criterion ‘Known chronic kidney disease stages 3–5′ was amended to ‘Known chronic
kidney disease stages 3b-5’
7 August 2014
Guidance for renal functioning monitoring updated 9 January 2014
Further guidance for monitoring side effects and loss to follow-up added 9 January 2014
Additional exclusion criterion added: uncontrolled serious concomitant illness 9 January 2014
Removed from exclusion criteria: pregnancy and lactation; diagnosis of MCI; lacks capacity to
give informed consent; and severe liver disease
9 January 2014
Broadened recruitment strategy by allowing members of the research team to get patient
consent after patients had been initially approached by the study doctor
14 October 2013
Guidance on reporting SAEs/SUSARs added 28 August 2013
Changed frequency of safety checks from every 6 months to every 3 months 28 August 2013
Broadened recruitment strategy by advertising the study and allowing potentially interested
individuals to contact the research team directly
28 August 2013
Added age range (≥ 50 years) to inclusion criterion 28 August 2013
JDR, Joint Dementia Research; MCI, mild cognitive impairment; SUSAR, suspected unexpected serious adverse reaction.
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Appendix 2 Literature search
Table 6 presents a summary of the number of articles identified by each search engine.
The following URL provides a link to the PROSPERO record for the search:
www.crd.york.ac.uk/prospero/display_record.php?RecordID = 90377 9 (accessed April 2018).
The following search terms were used in March 2018 to perform the search:
minocycline AND (AD OR alzheimer OR MCI OR “mild cognitive impairment” OR dementia).
TABLE 6 Literature search
Search engine Number of articles identified
PubMed 1549
The Cochrane Library 19
Web of Science 121
Ovid (including EMBASE, PsycARTICLES and PsycINFO) 1471
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Appendix 3 Outcome measure response
sheets and sample participant responses
TABLE 7 The sMMSE outcome measure response sheet
Question Time allowed Score
1 What year is this? 10 seconds
Which season is this? 10 seconds
What month is this? 10 seconds
What is today’s date? 10 seconds
What day of the week is this? 10 seconds
2 What country are we in? 10 seconds
What province are we in? 10 seconds
What city/town are we in? 10 seconds
IN HOME – What is the street address of this house?
IN FACILITY – What is the name of this building?
10 seconds
IN HOME – What room are we in?
IN FACILITY – What floor are we on?
10 seconds
3 SAY: I am going to name three objects. When I am finished, I want you to repeat them.
Remember what they are because I am going to ask you to name them again in a few
minutes. Say the following words slowly at 1-second intervals – ball/car/man
20 seconds
4 Spell the word WORLD. Now spell it backwards. 30 seconds
5 Now what were the three objects I asked you to remember? 10 seconds
6 SHOW wristwatch. ASK: What is this called? 10 seconds
7 SHOW pencil. ASK: What is this called? 10 seconds
8 SAY: I would like you to repeat this phrase after me: No ifs, ands or buts. 10 seconds
9 SAY: Read the words on the page and then do what it says. Then hand the person the
sheet with CLOSE YOUR EYES on it. If the subject reads and does not close their eyes,
repeat up to three times. Score only if subject closes eyes
10 seconds
10 HAND the person a pencil and paper. SAY: Write any complete sentence on that piece of
paper. (Note: The sentence must make sense. Ignore spelling errors)
30 seconds
11 PLACE design, eraser and pencil in front of the person. SAY: Copy this design please
Allow multiple tries. Wait until person is finished and hands it back. Score only for a
correctly copied diagram with a 4-sided figure between two 5-sided figures
1 minute
12 ASK the person if they are right- or left-handed. Take a piece of paper and hold it up
in front of the person. SAY: Take this paper in your right/left hand (whichever is
non-dominant), fold the paper in half once with both hands and put the paper down
on the floor. Score 1 point for each instruction executed correctly:
l Takes paper correctly in hand
l Folds it in half
l Puts it on the floor
30 seconds
Total test score /30
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FIGURE 4 Bristol Activities of Daily Living Scale: outcome measure responses sheet. (continued )
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FIGURE 4 Bristol Activities of Daily Living Scale: outcome measure responses sheet. (continued )
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FIGURE 4 Bristol Activities of Daily Living Scale: outcome measure responses sheet. (continued )
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FIGURE 4 Bristol Activities of Daily Living Scale: outcome measure responses sheet.
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FIGURE 5 Sample participant responses: BADLS responses for 12 months’ follow-up. (continued )
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FIGURE 5 Sample participant responses: BADLS responses for 12 months’ follow-up.
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FIGURE 6 Sample participant responses: sMMSE responses for 12 months’ follow-up.
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Appendix 4 Additional figures and tables
TABLE 8 Follow-up rates for sMMSE and BADLS by treatment arm and time point
Time point Treatment arm
Assessment
sMMSE BADLS
Received (n) Expecteda (n) % Received (n) Expectedb (n) %
Screening 400mg of minocycline 183 184 99.5 183 184 99.5
200mg of minocycline 181 181 100 181 181 100
Placebo 178 179 99.4 177 178 99.4
Total 542 544 99.6 541 543 99.6
6 months 400mg of minocycline 159 184 86 159 184 86
200mg of minocycline 172 181 95 172 181 95
Placebo 167 179 93 164 176 93
Total 498 544 92 495 541 91
12 months 400mg of minocycline 139 181 77 140 180 78
200mg of minocycline 158 180 88 157 178 88
Placebo 156 176 89 155 171 91
Total 453 537 84 452 529 85
18 months 400mg of minocycline 127 179 71 128 178 72
200mg of minocycline 146 177 82 146 169 86
Placebo 147 172 85 148 167 89
Total 420 528 80 422 514 82
24 months 400mg of minocycline 119 174 68 118 170 69
200mg of minocycline 144 176 82 142 167 85
Placebo 140 167 84 137 154 89
Total 403 517 78 397 491 81
a Expected numbers of sMMSE assessments excluding those participants who withdrew prior to starting treatment
(i.e. those participants not effectively randomised and those who died prior to the assessment).
b Expected numbers of BADLS assessments also excluding those participants who were admitted to care.
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TABLE 9 Skin toxicity incidence and severity by treatment arm
Treatment arm Toxicity rating Number of patients
400mg of minocycline Mild 33
Moderate 27
Severe 1
Subtotal 61
200mg of minocycline Mild 38
Moderate 29
Severe 2
Subtotal 69
Placebo Mild 22
Moderate 13
Severe 3
Subtotal 38
TABLE 10 Causes of death
Treatment arm Cause of death
Weeks
until death
Stopped treatment
≥ 28 days previously?
Infection
Placebo Infection 64 Yes – 17 weeks
Placebo Pneumonia 36 No
Placebo Pneumonia and pulmonary oedema 28 Yes – 23 weeks
Placebo Pneumonia 66 No
Placebo Chest infection 83 No
200mg of minocycline Pneumonia 56 No
400mg of minocycline Pneumonia 86 Yes – 2 weeks
Neuropsychiatric
Placebo Dementia 95 No
Placebo AD/Lewy body dementia 92 Yes – 87 weeks
400mg of minocycline Progression of AD 58 Yes – 7 weeks
Cardiovascular
Placebo Myocardial infarction 102 No
Placebo Myocardial infarction 72 No
Placebo Heart attack 64 No
200mg of minocycline Cardiac event 50 No
200mg of minocycline Heart attack 58 Yes – 51 weeks
400mg of minocycline Heart attack 37 No
400mg of minocycline Heart failure 100 Yes – 88 weeks
400mg of minocycline Heart attack 91 No
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TABLE 10 Causes of death (continued )
Treatment arm Cause of death
Weeks
until death
Stopped treatment
≥ 28 days previously?
Cerebrovascular
200mg of minocycline Unknown (stroke on 21 March 2017) 103 Yes – 84 weeks
400mg of minocycline CVA 42 Yes – 3 weeks
400mg of minocycline Stroke 36 No
Renal failure
Placebo Chronic renal failure 32 Yes – 12 weeks
400mg of minocycline Lung and kidney failure 103 Yes – 1 week
Other cause
Placebo Complications after bowel surgery 89 Yes – 44 weeks
200mg of minocycline General health decline 56 Yes – 29 weeks
200mg of minocycline Large abdominal tumour causing kidney failure 28 Never started
400mg of minocycline COPD 57 Yes – 11 weeks
Unknown
400mg of minocycline Unknown 77 Yes – 17 weeks
COPD, chronic obstructive pulmonary disorder; CVA, cerebrovascular accident.
400 mg of minocycline vs. placebo; p < 0.0001
200 mg of minocycline vs. placebo; p = 0.56
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FIGURE 7 Proportion of participants taking trial treatment over time: Kaplan–Meier plot.
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Screening
6 months
12 months
18 months
24 months
453 had sMMSE at 12 months: 139, 158, 156
(453 patients had assessment + 48 + 41 + 2 without)
420 had sMMSE at 18 months: 127, 146, 147
(420 patients had assessment + 40 + 41 + 41 + 2 without)
40 patients missing 18-month assessment
• 7 just missing 18-month assessment
• 3 missing 12-  and 18-month assessments
• 30 no more follow-up – 7 died before reaching
   18 months and 1 died after 18 months: 11, 11, 8
Patients allocated treatment pack
(n = 554)
Patients who never started trial medication 
(n = 10)
Patients randomised
(n = 544)
2 patients followed up no more: 1, 1
498 had sMMSE at 6 months: 159, 172, 167
(498 patients had assessment + 44 + 2 without)
44 patients missing 6-month assessment
• 1 just missing 6-month assessment
• 2 missing 6- and 24-month assessments
• 41 no more follow-up –2 died after 6 months: 22,
    9, 10
542 had sMMSE screening: 183, 181, 178
(542 patients had assessment + 2 without)
48 patients missing 12-month assessment
• 2 just missing 12-month assessment 
• 3 missing 12- and 18-month assessments
• 2 missing 12-  and 24-month assessments
• 41 no more follow-up – 4 died before reaching
    12 months and 4 died after 12 months: 21, 11, 9
403 had sMMSE at 24 months: 119, 144, 140
(403 patients had assessment + 27 + 30 + 41 + 41 +
2 without)
27 patients missing 24-month assessment
• 15 just missing 24-month assessment: 5, 5, 5
• 2 missing 6- and 24-month assessments: 1, 1
• 2 missing 12- and 24-month assessments: 2
• 8 died before 24-month assessment
• Died before month 9, n = 1
FIGURE 8 Flow chart showing the completeness over time of participant follow-up. Colour coding to show assessments
split by treatment arm: navy font is 400mg of minocycline, light blue font is 200 mg of minocycline and red font is placebo.
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FIGURE 9 Change in sMMSE and BADLS scores from baseline to month 24 using imputation methods 1 (a and b) and
2 (c and d). A to estimate scores for patients with no follow-up past baseline. Graph shows change in mean sMMSE and BADLS
scores with standard errors. Baseline scores are set to zero and p-values are from tests for time-by-treatment interaction from
repeated measures analyses. (a) Average change in sMMSE score from baseline to month 24, using imputation (baseline scores
are 26.3 points for 400mg of minocycline, 26.5 points for 200mg of minocycline and 26.4 points for placebo). (b) Average
change in BADLS score from baseline to month 24, using imputation (baseline scores are 5.6 points for 400mg of minocycline,
4.9 points for 200mg of minocycline and 5.5 points for placebo). (c) Average change in sMMSE score from baseline to month
24 using imputation. (d) Average change in BADLS score from baseline to month 24, using imputation. (continued )
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FIGURE 9 Change in sMMSE and BADLS scores from baseline to month 24 using imputation methods 1 (a and b) and
2 (c and d). A to estimate scores for patients with no follow-up past baseline. Graph shows change in mean sMMSE and BADLS
scores with standard errors. Baseline scores are set to zero and p-values are from tests for time-by-treatment interaction from
repeated measures analyses. (a) Average change in sMMSE score from baseline to month 24, using imputation (baseline scores
are 26.3 points for 400mg of minocycline, 26.5 points for 200mg of minocycline and 26.4 points for placebo). (b) Average
change in BADLS score from baseline to month 24, using imputation (baseline scores are 5.6 points for 400mg of minocycline,
4.9 points for 200mg of minocycline and 5.5 points for placebo). (c) Average change in sMMSE score from baseline to month
24 using imputation. (d) Average change in BADLS score from baseline to month 24, using imputation.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
– 5 – 4 – 3 – 2 – 1 0 1 2 3 4 5
Duration of symptoms
< 6 months
≥ 6 months
Baseline MMSE
24 – 26
27 – 30
Age (years)
< 65
65 – 74
≥ 75
Sex
Female
Male
0.87
 
0.46
 
 
0.04
 
 
 
0.66
Treatment effectSubgroup p-value
---Min. better  --  Min. worse---
FIGURE 10 Subgroup analyses of change in sMMSE score over 24 months for minocycline (any dose) vs. placebo by
baseline characteristics: duration of symptoms, baseline sMMSE score, age and gender. Results are derived from a
repeated measures model, with p-values from tests for interaction between treatment and the selected subgroup.
Min., minimum. The p-value is from the test statistic for testing the interaction between the treatment and any
subgroup variable.
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FIGURE 11 Probability of (a) overall survival, (b) institutionalisation and (c) time to death or institutionalisation by
treatment arm: Kaplan–Meier survival plots. (continued )
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FIGURE 11 Probability of (a) overall survival, (b) institutionalisation and (c) time to death or institutionalisation by
treatment arm: Kaplan–Meier survival plots.
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FIGURE 12 Average decline of sMMSE score split by baseline sMMSE score (i.e. a score of 24–26 or 27–30a points).
a, Eight patients start with a sMMSE score of 30 points and have a 24-month sMMSE score of 30 points.
TABLE 11 Line-by-line listings of categoriseda SAEs
Reference
number of SAE SAE On treatment?
Gastrointestinal
SAE031 Gastroenteritis Yes
SAE067 Constipation. Was taken to hospital, patient described medication Yes
SAE064 Gastroenteritis Yes
SAE077 Sigmoid volvulus with faecal impaction Stopped > 28 days ago
SAE075 Diverticulitis and impacted bowel Yes
SAE087 Deranged LFTs/stomach ulcer with gastrointestinal bleed Yes (stopped same time)
SAE149 Abdominal distension pain Stopped > 28 days ago
SAE091 Constipation. Admitted to hospital with sickness/stomach pains Stopped < 28 days ago
SAE095 Gradual internal bleeding of the stomach lining Yes
SAE092 Diarrhoea, vomiting and weight loss. Ambulance called and patient
was admitted to hospital overnight. Hospital-requested RNI scan
Yes
SAE106 Under investigation – severe diarrhoea. Bowels going into spasms Yes
SAE112 Patient admitted to hospital with severe abdominal pains Stopped > 28 days ago
continued
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TABLE 11 Line-by-line listings of categoriseda SAEs (continued )
Reference
number of SAE SAE On treatment?
SAE120 Undiagnosed stomach pains. Investigations into possible stomach ulcer
or recurrence of bowel cancer
Yes (stopped same time)
SAE138 Diverticulitis Yes
SAE181 Gastroenteritis Yes
SAE164 Appendicitis Yes
SAE187 Death from complications after bowel surgery Stopped > 28 days ago
SAE209 Secondary, adhesion bowel obstruction – resulted in death Stopped > 28 days ago
SAE194 Bowel obstruction Yes
SAE182 Cyst on small intestine updated diagnosis previously bowel
obstruction
Yes
SAE228 Obstruction of the common bile duct Yes
Respiratory
SAE001 Pneumonia Yes (stopped same time)
SAE002 Wheezing and shortness of breath Yes (stopped same time)
SAE012 COPD Yes
SAE020 Pneumonia Yes
SAE018 Pneumonia – resulted in death Yes (stopped same time)
SAE022 Suicide attempt and subsequent aspiration pneumonia and pulmonary
oedema – resulted in death
Stopped > 28 days ago
SAE025 Community-acquired pneumonia Yes (stopped same time)
SAE048 Sepsis secondary to community-acquired pneumonia Yes (stopped same time)
SAE043 Pneumonia Yes
SAE047 Suspected pneumonia/further investigation Yes
SAE079 Pneumonia and pleural effusion – resulted in death Yes
SAE085 Pneumonia Yes (stopped same time)
SAE116 Died – COPD Stopped > 28 days ago
SAE114 Pneumonia – died in hospital Yes (stopped same time)
SAE117 Pneumonia preceded by declining neutrophil count which then rose
before ceasing IMP
Yes
SAE136 Community-acquired pneumonia Yes
SAE122 Pneumonia Yes
SAE156 Increased shortness of breath Stopped < 28 days ago
SAE163 Breathlessness and extreme thirst Yes
SAE184 Pneumonia Yes
SAE200 COPD Yes
SAE226 Admitted to hospital after fall and contracted pneumonia while in
hospital
Yes
SAE266 Admitted to hospital after fall and contracted pneumonia while in
hospital. Had fractured a rib
Yes
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TABLE 11 Line-by-line listings of categoriseda SAEs (continued )
Reference
number of SAE SAE On treatment?
SAE243 Pneumonia Stopped > 28 days ago
SAE270 Pulmonary fibrosis Yes
SAE215 Pneumonia – resulted in death Stopped > 28 days ago
Mechanical injury
SAE004 Fall resulting in skull fracture Yes
SAE015 Fall and closed fracture of rib Yes (stopped same time)
SAE021 Fall out of bed resulting in head and neck injury Stopped < 28 days ago
SAE034 Fall sustaining cuts, bruising and reduced mobility Yes
SAE053 Unwitnessed fall out of bed Yes
SAE068 Fractured pubic rami from a fall Yes
SAE046 Fracture of right femur from a fall Yes (stopped same time)
SAE054 Fractured wrist from a fall Yes
SAE080 Patient fell and fractured pelvis, related to increased dizziness,
less steady on feet since starting MADE trial treatment
Stopped < 28 days ago
SAE063 Possible bruised, cracked or broken ribs following a fall as a result of
tripping
Yes
SAE073 Shoulder surgery following fall and dislocation Yes
SAE065 Fractured right humerus from a fall Yes
SAE093 Cerebral concussion and cut to head from a fall Yes
SAE124 Fractured right neck of femur Yes (stopped same time)
SAE155 Road traffic accident – patient hit by car Stopped > 28 days ago
SAE119 Fall and admission to hospital overnight Yes
SAE139 Fractured left femur and underwent left hemiarthroplasty Yes
SAE175 Fractured ribs from a fall Yes
SAE117 Broken left hip Yes
SAE196 Fracture of left neck of femur Yes
SAE199 Knee replacement operation Yes
SAE222 Fall Yes
SAE232 Fracture of metacarpal Yes
SAE235 Facial injury from a fall Stopped > 28 days ago
SAE237 Collapse and facial injury and nasal fracture Yes
SAE254 Fractured hip Yes
SAE255 Fall causing pubic ramus and wrist fracture Yes
SAE258 Vertigo/dizziness – leading to head injury from a fall Stopped > 28 days ago
SAE256 Fracture to middle finger and left hand Yes
SAE263 Mechanical fall and back pain Stopped > 28 days ago
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TABLE 11 Line-by-line listings of categoriseda SAEs (continued )
Reference
number of SAE SAE On treatment?
Endocrine and metabolic
SAE008 Diabetes mellitus management impairment – resolved Yes
SAE007 New medical diagnosis of type 2 diabetes mellitus Yes
SAE060 Low sodium levels Yes
SAE061 Pituitary adenoma Stopped > 28 days ago
SAE056 Diabetic ketoacidosis Stopped > 28 days ago
SAE072 Hypoglycaemia Stopped > 28 days ago
SAE118 Hypoglycaemia Yes
SAE132 Syndrome of inappropriate anti-diuretic hormone Yes
SAE135 Low potassium levels as a result of bowel preparation for CT
bowel scan
Yes
SAE189 Admitted to hospital after feeling weak and faint. Diagnosed with low
sodium levels
Yes
SAE190 Admitted to hospital following low sodium levels and generally
feeling weak
Yes
SAE249 Inflammatory arthropathy – probably due to gout Yes
Cancer
SAE005 Recurrence of bladder cancer Yes
SAE032 Tumour on kidney – right kidney/part of liver removed Yes
SAE024 Colon cancer Yes
SAE040 Colon cancer (open anterior resection surgery) Yes
SAE066 Chronic lymphocytic leukaemia Yes
SAE096 Diagnosis of myeloproliferative neoplasm JAK1 Yes
SAE078 Working diagnosis – colon cancer. Patient feels well so patient/family
do not want further tests
Yes
SAE083 Bowel cancer – resulted in death Yes
SAE011 Cancer of oesophagus Stopped > 28 days ago
SAE123 Suspected kidney cancer, diagnosis of left renal tumour Stopped > 28 days ago
SAE229 Chronic lymphoid leukaemia Stopped > 28 days ago
SAE102 Recent lung cancer diagnosis. Further investigation of cancer shows it
to be terminal with secondary cancers in the liver
Yes
SAE109 Bowen’s disease Yes
SAE183 MDS Yes
SAE147 Bowel cancer Stopped > 28 days ago
SAE130 Probable lung cancer, will not undergo treatment for cancer Stopped > 28 days ago
SAE142 Patient diagnosed with prostate cancer Yes
SAE161 Prostate cancer with pelvic metastasis Yes
SAE191 Colonic primary tumour, with extensive liver metastasis Stopped < 28 days ago
SAE193 Complex atypical hyperplasia Yes (stopped same time)
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TABLE 11 Line-by-line listings of categoriseda SAEs (continued )
Reference
number of SAE SAE On treatment?
SAE206 Lung tumour and secondary cancers Yes
SAE212 Appearances consistent with lung malignancy. Given comorbid
condition for best supportive/palliative care
Yes
SAE217 Vulvar cancer Yes
SAE238 Tonsillectomy as a result of cancer Yes
SAE251 Prostate cancer Stopped > 28 days ago
SAE253 Basal cell carcinoma Yes
Haematological/thrombosis
SAE038 Low levels of platelets Yes (stopped same time)
SAE045 Blood transfusion for suspected bleed, following low levels of
haemoglobin
Yes
SAE110 DVT Yes (stopped same time)
SAE129 Neutropenia Yes
SAE145 Anaemia Yes
SAE236 Blood clot Yes
Dermatological
SAE245 Minocycline type 2 pigmentation on face Yes
Neuropsychiatric
SAE009 Hospitalisation following seizures Yes
SAE019 Psychosis secondary to dementia. Also mild UTI Yes (stopped same time)
SAE029 Admitted to psychiatric unit following relapse in psychotic symptoms
with agitation
Stopped > 28 days ago
SAE128 Patient confused, lacked co-ordination and had been experiencing
more falls for a few weeks
Yes
SAE160 Hospital admission with severe Alzheimer’s dementia, with significant
behavioural disturbance
Stopped > 28 days ago
SAE050 Admission to hospital as a result of loss of consciousness Yes
SAE158 Death as a result of dementia Yes
SAE016 Subdural haematoma Yes (stopped same time)
SAE152 AD/Lewy body disease – resulted in death Stopped < 28 days ago
SAE143 Stroke Yes (stopped same time)
SAE105 Probable stroke. Also receiving treatment for chest infection Yes (stopped same time)
SAE055 Minor stroke Yes
SAE146 Seizure (known epilepsy), cracked bone in ankle Yes
SAE086 CVA – resulted in death Stopped > 28 days ago
SAE170 AD Yes
SAE076 AD Yes
SAE203 Minor stroke non-haemorrhagic Yes
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TABLE 11 Line-by-line listings of categoriseda SAEs (continued )
Reference
number of SAE SAE On treatment?
SAE069 Stroke Yes
SAE059 Left intracranial bleed Yes (stopped same time)
SAE154 AD Yes
SAE166 Funny turns followed by suspected TIA. Patient hospitalised Stopped > 28 days ago
SAE150 Stroke Yes
SAE167 Bleeding on brain Yes
SAE159 Mini stroke (TIA) Yes
SAE169 Suspected stroke/seizure Yes
SAE172 Stroke – resulted in death Yes
SAE088 Small left frontal lobe cortical haemorrhage Yes
SAE153 Subdural haemorrhage/blood clot Yes
SAE121 Admitted following falls, is due to being discharged home with
end-of-life/full-time carers. MRI scanning showed chronic subdural
haematoma
Yes (stopped same time)
SAE134 Seizure, no diagnosis given Stopped < 28 days ago
SAE218 Delirium Yes (stopped same time)
SAE219 Dementia in AD Yes
SAE198 Confusion, slurred speech, unsteady on feet. Admitted to hospital Yes
SAE230 Patient in acute psychiatric ward on section 2 Yes
SAE231 Suspected stroke. Patient died Stopped > 28 days ago
SAE239 Possible TIA Yes
SAE247 Delirium Yes
SAE252 Progression of AD – resulted in death Yes (stopped same time)
SAE265 CVA Yes (stopped same time)
Cardio-circulatory
SAE036 Suspected myocardial infarction Yes
SAE030 Shortness of breath and suspected MI Yes
SAE010 Cardiac abnormalities: long QT on ECG and impaired left ventricular
function
Yes
SAE062 Cardiac event – resulted in death Yes (stopped same time)
SAE035 Myocardial infarction Yes
SAE099 Syncope attributed to GTN spray overdose (accidental) Yes
SAE090 Swollen ankles, shortness of breath, ambulance called. Admitted to
hospital for 11 days. Diagnosis fluid on lungs and heart murmur
Yes
SAE104 Cardiogenic syncope Yes
SAE094 Collapsed, thought to be as a result of low blood pressure Yes
SAE098 Postural hypotension Yes
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TABLE 11 Line-by-line listings of categoriseda SAEs (continued )
Reference
number of SAE SAE On treatment?
SAE201 Out-of-hospital ventricular fibrillation arrest as a result of anterior
myocardial infarction – resulted in death
Yes (stopped same time)
SAE211 Recurrent gradual-onset syncope, junctional bradycardia on
implantable loop recorder
Yes
SAE208 Postural hypotension Yes
SAE039 Hospitalisation – low blood pressure/pulse rate Yes
SAE157 Hypotension Yes
SAE125 Chest pain Yes
SAE049 Suspected heart attack resulting in death Yes (stopped same time)
SAE137 Severe mitral valve regurgitation, which resolved on rate-limiting
control of AF and LV improvement in function
Yes
SAE144 Currently unknown – heart-related problems Yes
SAE151 Death from MI Yes (stopped same time)
SAE168 Death – coronary atherosclerosis hypertension Yes (stopped same time)
SAE171 Cardiac arrest Yes
SAE207 Heart problems. Cardiac monitor had revealed that heart had stopped
for short time
Yes
SAE202 Heart failure Stopped < 28 days ago
SAE205 Heart failure Stopped < 28 days ago
SAE176 Aortic stenosis Yes
SAE103 Deterioration in cardiac failure plus syncopal episode that led to
hospital admission
Yes (stopped same time)
SAE224 Heart failure – resulted in death Stopped > 28 days ago
SAE241 Heart attack – resulted in death Stopped > 28 days ago
SAE240 Labile blood pressure/hypertension Yes
SAE246 Heart failure Yes
SAE248 Heart attack – resulted in death Yes (stopped same time)
SAE564 Syncope (probably as a result of bradycardia) Stopped > 28 days ago
SAE268 Atrial fibrillation Stopped > 28 days ago
Renal
SAE057 Kidney stones Yes
SAE058 Large abdominal tumour causing kidney failure – resulted in death Never started
SAE084 Chronic renal failure – resulted in death Stopped > 28 days ago
SAE101 No evidence of bladder cancer. Patient was having tests from a
bladder biopsy
Yes
SAE113 Radical left nephrectomy laparoscopy Stopped > 28 days ago
SAE204 Acute kidney injury Yes
SAE267 Lung and kidney failure – resulted in death Stopped > 28 days ago
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TABLE 11 Line-by-line listings of categoriseda SAEs (continued )
Reference
number of SAE SAE On treatment?
Infection
SAE014 Hospitalisation – chest infection Yes
SAE017 Hospitalisation – delirium as a result of dehydration and urine
infection
Yes
SAE044 Probable UTI, symptoms of confusion, weakness, low mobility Yes
SAE082 Infection following a foreign body in arm Yes
SAE051 Chest infection Yes (stopped same time)
SAE052 Urinary tract infection Yes (stopped same time)
SAE081 Catheter-associated UTI Yes (stopped same time)
SAE070 Chest infection Yes
SAE097 Infection – resulted in death Stopped > 28 days ago
SAE100 Pruritic rash in the context or urosepsis Yes
SAE107 Urosepsis Yes
SAE115 Sepsis, possibly related to gall bladder problems Stopped > 28 days ago
SAE131 Progressive decline post chest infection Stopped > 28 days ago
SAE127 Urinary infection Stopped < 28 days ago
SAE141 Admitted with lower respiratory infection Yes (stopped same time)
SAE165 Admitted to hospital with very sore throat later diagnosed
as thrush
Yes
SAE173 Shortness of breath and chest infection Yes
SAE174 Shortness of breath and chest infection Yes
SAE180 Taken to hospital with very low blood pressure and infection Yes
SAE188 Sepsis Stopped > 28 days ago
SAE195 On 11 November 2016 wife reports participant has chest infection –
resulted in death
Yes (stopped same time)
SAE197 Urinary tract infection Yes
SAE133 Updated from discharge summary: cellulitis Stopped > 28 days ago
SAE233 UTI Stopped > 28 days ago
SAE234 UTI Stopped > 28 days ago
SAE210 Urinary tract infection, confusion Yes
SAE216 Oesophageal candidiasis Yes
SAE213 Admitted with lower respiratory tract infection Stopped > 28 days ago
SAE22 UTI Yes
SAE223 UTI Yes
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TABLE 11 Line-by-line listings of categoriseda SAEs (continued )
Reference
number of SAE SAE On treatment?
Other
SAE006 Hospitalisation – collapsed in street Yes
SAE028 Suspected blood clot in legs. Swollen legs/painful. No blood clot found Yes
SAE033 Suspected thrombosis – investigations complete no diagnosis of
thrombosis. Symptoms of swollen legs have been associated with
previously known water condition. Symptoms reduced after treatment
Yes
SAE042 Participant drank white spirit in error Yes
SAE071 Replacement of left knee Stopped > 28 days ago
SAE111 Sensitivity and tenderness around left nipple Yes
SAE074 IMP overdose Yes
SAE089 Patient collapsed following accidental overdose of ranitidine Yes (stopped same time)
SAE108 General health decline – resulted in death. Patient was in respite care Stopped > 28 days ago
SAE148 Osteoarthritis Yes
SAE179 Jaw, back and neck pain – no diagnosis – cardiac problems ruled out Stopped > 28 days ago
SAE162 Prolonged hospital stay after planned hernia operation Yes
SAE186 Admitted for elective abdominal hysterectomy and bilateral
salpingo-oophorectomy
Yes
SAE178 No acute medical problem identified. Patient felt as if she had severe
indigestion. Investigations into whether or not it was a mild heart
attack in A&E (stayed overnight). No explanation found
Stopped > 28 days ago
SAE185 TURP Yes
SAE214 Hip screw removal Yes
SAE225 Yes
SAE244 Postoperative scrotal oedema Yes
SAE242 Swollen legs Yes
SAE250 Unknown – resulted in death > 28 days ago
A&E, accident and emergency; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disorder; CT, computed
tomography; CVA, cerebrovascular accident; DVT, deep-vein thrombosis; ECG, electrocardiogram; GTN, glyceryl
trinitrate; JAK1, Janus kinase 1; LFT, liver function test; LV, left ventricular; MDS, myelodysplastic syndrome;
MI, myocardial infarction; MRI, magnetic resonance imaging; RNI, radionucleotide; TIA, transient ischaemic attack;
TURP, transurethral resection of the prostate; UTI, urinary tract infection.
a Participants can have more than one recorded SAE in each category.
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